Drug delivery systems comprising neurotrophic agent, apoptosis signaling fragment inhibitor (FAS) or fas ligand (FASL) inhibitor, tumor necrosis factor-α (TNF-α) or TNF receptor inhibitor, mitochondrial peptide, oligonucleotide, chemokine inhibitor, or cysteine-aspartic protease

Abstract

To provide a drug delivery system to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction.SOLUTION: A drug delivery system comprises a first active pharmaceutical ingredient (API) and a sustained delivery component, wherein the first API is a peptide derivative of ciliary neurotrophic factor (CNTF) comprising the peptide sequence DGGL, and the first API is a peptide represented by SEQ ID NO: 2 (peptide 21: Ac-DGGLAG-NH2). The drug delivery system is used for injection into mammal eyes.SELECTED DRAWING: None

Description

[Technical Field]

[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Patent Application No. 62 / 687,173, filed June 19, 2018, U.S. Provisional Patent Application No. 62 / 725,972, filed August 31, 2018, U.S. Provisional Patent Application No. 62 / 747,575, filed October 18, 2018, and U.S. Provisional Patent Application No. 62 / 787,873, filed January 3, 2019, the entire contents of which are incorporated herein by reference. PCT / US19 / 37774, filed June 18, 2019, is also incorporated herein by reference in its entirety.

[0002] (Sequence Listing) This application contains a Sequence Listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy, created on June 18, 2019, has the file name V3563_10002WO01_SL.txt and is 4,697 bytes in size. Summary of the Invention [Problem to be solved by the invention]

[0003] The present disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor alpha (TNF-α) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic acid protease (including any combination of these compounds), and optionally a sustained-delivery component. This type of drug delivery system can be used to treat conditions such as hereditary or age-related choroidal, retinal, or optic nerve disease or degeneration of the optic nerve; hearing impairment; neurological or CNS disorders; or related symptoms; or conditions associated with blockage or impairment of blood vessels or blood circulation, such as stroke, myocardial infarction, renal infarction, etc. [Means for solving the problem]

[0004] Some embodiments include a drug delivery system comprising a first active pharmaceutical ingredient (API) and a sustained delivery component, wherein the first API is a neurotrophic agent, a FAS / FASL inhibitor, a TNF-α / TNFR inhibitor, a mitochondrial peptide, a chemokine inhibitor, a cysteine-aspartic acid protease, or a combination thereof.

[0005] Some embodiments include methods of treating a condition including 1) a genetic or age-related disorder or degeneration of the choroid, retina, or optic nerve, 2) an ear disorder, or 3) a neurological or CNS disorder, comprising administering a drug delivery system described herein to a mammal in need of treatment.

[0006] Use of a FAS / FASL inhibitor, a TNF-α / TNFR inhibitor, a mitochondrial peptide, a chemokine inhibitor, a cysteine-aspartic acid protease, or a combination thereof in the manufacture of a drug delivery system for the treatment of 1) a genetic or age-related disorder or degeneration of the choroid, retina, or optic nerve, 2) an ear disorder, or 3) a neurological or CNS disorder, wherein the drug delivery system further includes a sustained delivery component.

[0007] A kit comprising a drug delivery system described herein and a label with instructions for using the drug delivery system for the treatment of 1) a genetic or age-related disorder or degeneration of the choroid, retina, or optic nerve, 2) an ocular disorder, or 3) a neurological or CNS disorder. DETAILED DESCRIPTION OF THE INVENTION

[0008] With respect to the subject drug delivery systems, the neurotrophic agent can comprise a CNTF compound or other neurotrophic agent, where CNTF compounds include any compound with a structure or activity similar to ciliary neurotrophic factor (CNTF), including CNTF, a protein derivative of CNTF, or a CNTF peptide. Examples include CNTF, peptide 6 (P6; Ac-VGDGGLFEKKL-NH2 (SEQ ID NO: 1)), and peptide 21 (P21; Ac-DGGL A Neurotrophic peptides include peptides containing a portion of the sequence of CNTF, such as G-NH2 (SEQ ID NO: 2), recombinant CNTF (rhCNTF), or neurotrophic peptides containing adamantyl groups at the C-terminus and / or N-terminus, as described in U.S. Patent No. 8,592,374, the disclosure of which related to neurotrophic peptides is incorporated herein by reference, or any other peptides with biological activity similar to CNTF. Other neurotrophic agents include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), etc.

[0009] Any suitable amount of a neurotrophic agent, such as a CNTF compound, NGF, BDNF, or GDNF, can be used in the drug delivery system. For example, the drug delivery system can contain about 0.01-1 μg, about 1-2 μg, about 2-3 μg, about 3-4 μg, about 4-5 μg, about 5-6 μg, about 6-7 μg, about 7-8 μg, about 8-9 μg, about 9-10 μg, about 0.01-3 μg, about 3-6 μg, about 6-10 μg, about 0.01-10 μg, or about 10-20 μg. μg, approximately 20-30 μg, approximately 30-40 μg, approximately 40-50 μg, approximately 50-60 μg, approximately 60-70 μg, approximately 70-80 μg, approximately 80-90 μg, Approximately 90-100μg, approximately 0.01-30μg, approximately 30-60μg, approximately 60-100μg, approximately 0.01-100μg, approximately 0.1-100μg, approximately 10 The amount may comprise 0 to 200 μg, about 200 to 300 μg, about 300 to 400 μg, about 400 to 500 μg, about 500 to 600 μg, about 600 to 700 μg, about 700 to 800 μg, about 800 to 900 μg, about 900 to 1,000 μg, about 0.01 to 300 μg, about 300 to 600 μg, about 600 to 1,000 μg, about 0.01 to 1 mg, about 1 to 2 mg, about 2 to 3 mg, about 3 to 4 mg, about 4 to 5 mg, about 5 to 6 mg, about 6 to 7 mg, about 7 to 8 mg, about 8 to 9 mg, about 9 to 10 mg, about 0.01 to 3 mg, about 3 to 6 mg, about 6 to 10 mg, or about 0.01 to 10 mg of one of these compounds. These amounts may also apply to situations where the drug is present in a covalently bound form, such as with another agent or sustained delivery component.

[0010] The use of the above amounts of a neurotrophic agent, such as a CNTF compound, NGF, BDNF, GDNF, etc., in a drug delivery system can provide a drug delivery system that provides therapeutic concentrations of the neurotrophic agent for a period of about 1-4 weeks, about 1-3 months, about 3-6 months, about 6-9 months, about 9-12 months, about 12-18 months, about 18-24 months, about 2-5 years, about 5-10 years, or longer.

[0011] Useful FAS or FASL inhibitors include bicyclol, FLIP; MET12 (HHIYLGAVNYIY (SEQ ID NO: 3), HHIYLGATNYIY (SEQ ID NO: 4), or H 60 HIYLGATNYIY 71(SEQ ID NO:4)), or shorter fragments thereof, such as a tetramer, having the sequence YLGA (SEQ ID NO:5), or fragments having a sequence at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% homology to MET12, including compounds having a sequence shown in Table 1 below, such as Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, Compound 7, Compound 8, Compound 9, Compound 10, or Compound 11, ONL1204 (e.g., a peptide comprising or consisting of the sequence HHIYLGATNYIY (SEQ ID NO:4)); 60 HIYLGATNYIY 71 Other MET12 derivatives include compounds having -NH2 (SEQ ID NO: 4); FAS apoptosis inhibitor molecule [FAIM]; NOL3 [nucleolar protein 3 (suppressor of apoptosis with CARD domain [ARC]), etc.]; human decoy receptor 1 (DcR1); human decoy receptor 2 (DcR2); or human decoy receptor 3 (DcR3).

[0012] [ka]

[0013] [Table 1]

[0014] Any suitable amount of bicyclol, FLIP, Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, Compound 7, Compound 8, Compound 9, Compound 10, Compound 11, ONL1204, H 60 HIYLGATNYIY 71FAS or FASL inhibitors such as -NH2 (SEQ ID NO: 4), FAIM, NOL3, DcR1, DcR2, and DcR3 can be used in the drug delivery system. For example, the drug delivery system can be used in the following dosages: about 0.01-1 μg, about 1-2 μg, about 2-3 μg, about 3-4 μg, about 4-5 μg, about 5-6 μg, about 6-7 μg, about 7-8 μg, about 8-9 μg, about 9-10 μg, about 0.01-3 μg, about 3-6 μg, about 6-10 μg, about 0.01-10 μg, about 10-20 μg, about 20-30 μg, about 30-40 μg, about 40-50 μg, about 50-60 μg, about 60-70 μg, about 70-80 μg, about 80-90 μg, about 90-10 ...100-200 μg, about 200-300 μg, about 200-300 μg, about 200-300 μg, about 200-300 μg, about 200-300 μg, about 200-300 μg, about 200-300 μg μg, approx. 20-30 μg, approx. 30-40 μg, approx. 40-50 μg, approx. 50-60 μg, approx. 60-70 μg, approx. 70-80 μg, approx. 80-90 μg, Approximately 90-100μg, approximately 0.01-30μg, approximately 30-60μg, approximately 60-100μg, approximately 0.01-100μg, approximately 0.1-100μg, approximately 10 The amount may comprise 0 to 200 μg, about 200 to 300 μg, about 300 to 400 μg, about 400 to 500 μg, about 500 to 600 μg, about 600 to 700 μg, about 700 to 800 μg, about 800 to 900 μg, about 900 to 1,000 μg, about 0.01 to 300 μg, about 300 to 600 μg, about 600 to 1,000 μg, about 0.01 to 1 mg, about 1 to 2 mg, about 2 to 3 mg, about 3 to 4 mg, about 4 to 5 mg, about 5 to 6 mg, about 6 to 7 mg, about 7 to 8 mg, about 8 to 9 mg, about 9 to 10 mg, about 0.01 to 3 mg, about 3 to 6 mg, about 6 to 10 mg, or about 0.01 to 10 mg of one of these compounds. These amounts may also apply to situations where the drug is present in a covalently bound form, such as with another agent or sustained delivery component.

[0015] The above amounts of bicyclol, FLIP, Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, Compound 7, Compound 8, Compound 9, Compound 10, Compound 11, ONL1204, and H in the drug delivery system 60 HIYLGATNYIY 71 Use of a FAS or FASL inhibitor, such as -NH2 (SEQ ID NO: 4), FAIM, NOL3, DcR1, DcR2, or DcR3, can provide a drug delivery system that provides therapeutic concentrations of the FAS or FASL inhibitor for about 1-4 weeks, about 1-3 months, about 3-6 months, about 6-9 months, about 9-12 months, about 12-18 months, about 18-24 months, about 2-5 years, about 5-10 years, or longer.

[0016] Useful TNF-α or TNFR inhibitors include etanercept, infliximab, golimumab, certolizumab, adalimumab, TNF mutants that selectively antagonize TNFR1 (R1antTNF), DMS5540, TNF receptor 1 silencer (TROS), and ARROSAB.

[0017] Any suitable amount of a TNF-α or TNFR inhibitor, such as etanercept, infliximab, golimumab, certolizumab, adalimumab, R1antTNF, DMS5540, TROS, or ATROSAB, can be used in the drug delivery system. For example, the drug delivery system can contain about 0.01-1 μg, about 1-2 μg, about 2-3 μg, about 3-4 μg, about 4-5 μg, about 5-6 μg, about 6-7 μg, about 7-8 μg, about 8-9 μg, about 9-10 μg, about 0.01-3 μg, about 3-6 μg, about 6-10 μg, about 0.01-10 μg, or about 10-20 μg. μg, approximately 20-30 μg, approximately 30-40 μg, approximately 40-50 μg, approximately 50-60 μg, approximately 60-70 μg, approximately 70-80 μg, approximately 80-90 μg, Approximately 90-100μg, approximately 0.01-30μg, approximately 30-60μg, approximately 60-100μg, approximately 0.01-100μg, approximately 0.1-100μg, approximately 10 The amount may comprise 0 to 200 μg, about 200 to 300 μg, about 300 to 400 μg, about 400 to 500 μg, about 500 to 600 μg, about 600 to 700 μg, about 700 to 800 μg, about 800 to 900 μg, about 900 to 1,000 μg, about 0.01 to 300 μg, about 300 to 600 μg, about 600 to 1,000 μg, about 0.01 to 1 mg, about 1 to 2 mg, about 2 to 3 mg, about 3 to 4 mg, about 4 to 5 mg, about 5 to 6 mg, about 6 to 7 mg, about 7 to 8 mg, about 8 to 9 mg, about 9 to 10 mg, about 0.01 to 3 mg, about 3 to 6 mg, about 6 to 10 mg, or about 0.01 to 10 mg of one of these compounds. These amounts may also apply to situations where the drug is present in a covalently bound form, such as with another agent or sustained delivery component.

[0018] Use of the above amounts of a TNF-α or TNFR inhibitor, such as etanercept, infliximab, golimumab, certolizumab, adalimumab, R1antTNF, DMS5540, TROS, or ATROSAB, in a drug delivery system can provide a drug delivery system that provides therapeutic concentrations of the TNF-α or TNFR inhibitor for about 1 to 4 weeks, about 1 to 3 months, about 3 to 6 months, about 6 to 9 months, about 9 to 12 months, about 12 to 18 months, about 18 to 24 months, about 2 to 5 years, about 5 to 10 years, or longer.

[0019] Useful mitochondrial peptides include humanin, humanin analogs (eg, s14G-humanin, MTP101, elamipretide, etc.).

[0020] Any suitable amount of a mitochondrial peptide, such as humanin, humanin analog, s14G-humanin, MTP101, or elamipretide, can be used in the drug delivery system. For example, the drug delivery system can contain about 0.01-1 μg, about 1-2 μg, about 2-3 μg, about 3-4 μg, about 4-5 μg, about 5-6 μg, about 6-7 μg, about 7-8 μg, about 8-9 μg, about 9-10 μg, about 0.01-3 μg, about 3-6 μg, about 6-10 μg, about 0.01-10 μg, or about 10-20 μg. g, about 20-30μg, about 30-40μg, about 40-50μg, about 50-60μg, about 60-70μg, about 70-80μg, about 80-90μg, about 90~100μg, approx. 0.01~30μg, approx. 30~60μg, approx. 60~100μg, approx. 0.01~100μg, approx. 0.1~100μg, approx. 100 The amount of one of these compounds may be about 200 μg, about 200-300 μg, about 300-400 μg, about 400-500 μg, about 500-600 μg, about 600-700 μg, about 700-800 μg, about 800-900 μg, about 900-1,000 μg, about 0.0100-300 μg, about 300-600 μg, about 600-1,000 μg, about 0.01-1 mg, about 1-2 mg, about 2-3 mg, about 3-4 mg, about 4-5 mg, about 5-6 mg, about 6-7 mg, about 7-8 mg, about 8-9 mg, about 9-10 mg, about 0.01-3 mg, about 3-6 mg, about 6-10 mg, or about 0.01-10 mg. These amounts may also apply to situations where the drug is present in a covalently bound form, such as with another agent or sustained delivery component.

[0021] Use of the above amounts of mitochondrial peptides, such as Humanin, Humanin analogs, s14G-Humanin, MTP101, elamipretide, etc., in a drug delivery system can provide a drug delivery system that provides therapeutic concentrations of the mitochondrial peptide for about 1-4 weeks, about 1-3 months, about 3-6 months, about 6-9 months, about 9-12 months, about 12-18 months, about 18-24 months, about 2-5 years, about 5-10 years, or longer.

[0022] Useful oligonucleotides include DNA, RNA, and the like. In some embodiments, the oligonucleotide is a short inhibitory RNA, or "siRNA." siRNAs can induce the RNA interference (RNAi) pathway. siRNAs vary in length (typically 20-25 base pairs) and have varying degrees of complementarity to the target mRNA in the antisense strand. Some, but not all, siRNAs have unpaired overhangs at the 5' or 3' ends of the sense and / or antisense strands. siRNAs include duplexes of two separate strands, as well as single strands that can form hairpin structures containing duplex regions. In some embodiments, the siRNA targets FAS (as an siRNA targeted to FAS), such as FAS siRNA sense (5'-GAAACGAACUGCACCCGGAU-3' (SEQ ID NO: 16)) or negative siRNA sense (5'-UAGCGACUAAACACAUCAA-3' (SEQ ID NO: 17)). In some embodiments, the siRNA targets TNF-α.

[0023] Any suitable amount of oligonucleotides, such as DNA, RNA, siRNA, siRNA targeting FAS, FAS siRNA sense, negative siRNA sense, and siRNA targeting TNF-α, can be used in the drug delivery system. For example, the drug delivery system can be about 0.01 to 1 μg, about 1 to 2 μg, about 2 to 3 μg, about 3 to 4 μg, about 4 to 5 μg, about 5 to 6 μg, about 6 to 7 μg, about 7 to 8 μg, about 8 to 9 μg, about 9 to 10 μg, about 0.01 to 3 μg, about 3 to 6 μg, about 6 to 10 μg, about 0.01 to 10 μg, about 10 to 20 μg, or about 20 to 30 μg. μg, approx. 20-30 μg, approx. 30-40 μg, approx. 40-50 μg, approx. 50-60 μg, approx. 60-70 μg, approx. 70-80 μg, approx. 80-90 μg, Approximately 90-100μg, approximately 0.01-30μg, approximately 30-60μg, approximately 60-100μg, approximately 0.01-100μg, approximately 0.1-100μg, approximately 10 The amount may comprise 0 to 200 μg, about 200 to 300 μg, about 300 to 400 μg, about 400 to 500 μg, about 500 to 600 μg, about 600 to 700 μg, about 700 to 800 μg, about 800 to 900 μg, about 900 to 1,000 μg, about 0.01 to 300 μg, about 300 to 600 μg, about 600 to 1,000 μg, about 0.01 to 1 mg, about 1 to 2 mg, about 2 to 3 mg, about 3 to 4 mg, about 4 to 5 mg, about 5 to 6 mg, about 6 to 7 mg, about 7 to 8 mg, about 8 to 9 mg, about 9 to 10 mg, about 0.01 to 3 mg, about 3 to 6 mg, about 6 to 10 mg, or about 0.01 to 10 mg of one of these compounds. These amounts may also apply to situations where the drug is present in a covalently bound form, such as with another agent or sustained delivery component.

[0024] The use of the above amounts of DNA, RNA, siRNA, siRNA targeting FAS, FAS siRNA sense, negative siRNA sense, siRNA targeting TNF-α, and other oligonucleotides in a drug delivery system can provide a drug delivery system that provides therapeutic concentrations of oligonucleotide for about 1-4 weeks, about 1-3 months, about 3-6 months, about 6-9 months, about 9-12 months, about 12-18 months, about 18-24 months, about 2-5 years, about 5-10 years, or longer.

[0025] Useful chemokine inhibitors include NR58.3-14-3.

[0026] [ka]

[0027] Any suitable amount of a chemokine inhibitor such as NR58.3-14-3 can be used in the drug delivery system. For example, the drug delivery system can contain about 0.01-1 μg, about 1-2 μg, about 2-3 μg, about 3-4 μg, about 4-5 μg, about 5-6 μg, about 6-7 μg, about 7-8 μg, about 8-9 μg, about 9-10 μg, about 0.01-3 μg, about 3-6 μg, about 6-10 μg, about 0.01-10 μg, about 10-20 μg, or about 10-20 μg. μg, approximately 20-30 μg, approximately 30-40 μg, approximately 40-50 μg, approximately 50-60 μg, approximately 60-70 μg, approximately 70-80 μg, approximately 80-90 μg, Approximately 90-100μg, approximately 0.01-30μg, approximately 30-60μg, approximately 60-100μg, approximately 0.01-100μg, approximately 0.1-100μg, approximately 10 The amount may comprise 0 to 200 μg, about 200 to 300 μg, about 300 to 400 μg, about 400 to 500 μg, about 500 to 600 μg, about 600 to 700 μg, about 700 to 800 μg, about 800 to 900 μg, about 900 to 1,000 μg, about 0.01 to 300 μg, about 300 to 600 μg, about 600 to 1,000 μg, about 0.01 to 1 mg, about 1 to 2 mg, about 2 to 3 mg, about 3 to 4 mg, about 4 to 5 mg, about 5 to 6 mg, about 6 to 7 mg, about 7 to 8 mg, about 8 to 9 mg, about 9 to 10 mg, about 0.01 to 3 mg, about 3 to 6 mg, about 6 to 10 mg, or about 0.01 to 10 mg of one of these compounds. These amounts may also apply to situations where the drug is present in a covalently bound form, such as with another agent or sustained delivery component.

[0028] Use of the above amounts of a chemokine inhibitor, such as NR58.3-14-3, in a drug delivery system can provide a drug delivery system that provides therapeutic concentrations of the chemokine inhibitor for periods of about 1 to 4 weeks, about 1 to 3 months, about 3 to 6 months, about 6 to 9 months, about 9 to 12 months, about 12 to 18 months, about 18 to 24 months, about 2 to 5 years, about 5 to 10 years, or longer.

[0029] Useful cysteine-aspartic acid proteases (caspases) include caspase 2, caspase 3, caspase 8, caspase 9, and the like.

[0030] Any suitable amount of caspase, such as caspase 2, caspase 3, caspase 8, or caspase 9, can be used in the drug delivery system. For example, the drug delivery system can contain about 0.01 to 1 μg, about 1 to 2 μg, about 2 to 3 μg, about 3 to 4 μg, about 4 to 5 μg, about 5 to 6 μg, about 6 to 7 μg, about 7 to 8 μg, about 8 to 9 μg, about 9 to 10 μg, about 0.01 to 3 μg, about 3 to 6 μg, about 6 to 10 μg, about 0.01 to 10 μg, about 10 to 20 μg, or about 20 to 30 μg. μg, approximately 20-30 μg, approximately 30-40 μg, approximately 40-50 μg, approximately 50-60 μg, approximately 60-70 μg, approximately 70-80 μg, approximately 80-90 μg, Approximately 90-100μg, approximately 0.01-30μg, approximately 30-60μg, approximately 60-100μg, approximately 0.01-100μg, approximately 0.1-100μg, approximately 10 The amount may comprise 0 to 200 μg, about 200 to 300 μg, about 300 to 400 μg, about 400 to 500 μg, about 500 to 600 μg, about 600 to 700 μg, about 700 to 800 μg, about 800 to 900 μg, about 900 to 1,000 μg, about 0.01 to 300 μg, about 300 to 600 μg, about 600 to 1,000 μg, about 0.01 to 1 mg, about 1 to 2 mg, about 2 to 3 mg, about 3 to 4 mg, about 4 to 5 mg, about 5 to 6 mg, about 6 to 7 mg, about 7 to 8 mg, about 8 to 9 mg, about 9 to 10 mg, about 0.01 to 3 mg, about 3 to 6 mg, about 6 to 10 mg, or about 0.01 to 10 mg of one of these compounds. These amounts may also apply to situations where the drug is present in a covalently bound form, such as with another agent or sustained delivery component.

[0031] The use of the above amounts of a caspase, such as caspase 2, caspase 3, caspase 8, or caspase 9, in a drug delivery system can provide a drug delivery system that provides therapeutic levels of caspase for about 1-4 weeks, about 1-3 months, about 3-6 months, about 6-9 months, about 9-12 months, about 12-18 months, about 18-24 months, about 2-5 years, about 5-10 years, or longer.

[0032] The drug delivery system includes two different compounds that are neurotrophic agents, FAS / FASL inhibitors, TNF-α / TNFR inhibitors, mitochondrial peptides, oligonucleotides, chemokine inhibitors, or cysteine-aspartic acid proteases. For example, the first compound and the second compound can be those identified in Table 2.

[0033] [Table 2]

[0034] For each combination identified in Table 2, in some embodiments, the first compound and the second compound are covalently bonded to each other. In some embodiments, the first compound and the second compound are not covalently bonded to each other via a linking group.

[0035] For example, some combinations joined by a linking group are represented by Formulas 1, I, 2, A, B, D, E, F, G, H, J, K, M, N, O, P, Q, R, S, T and U [ka] It is expressed as:

[0036] In some embodiments, the drug delivery system includes a combination of the following drugs covalently attached (e.g., by a linking group L comprising a group of formula L-1, L-2, L-3, L-4, L-5, L-6, L-7, or L-8), including a salt, free acid, or free base of the drug: CNTF and a protein derivative of CNTF; CNTF and a CNTF peptide; CNTF and peptide 21; CNTF and peptide 21; CNTF and rhCNTF; CNTF and NGF; CNTF and BDNF; CNTF F and GDNF; CNTF and bicyclol; CNTF and FLIP; CNTF and MET12; CNTF and compound 1 in Table 1; CNTF and compound 2 in Table 1; CNTF and compound 3 in Table 1; CNTF and compound 4 in Table 1; CNTF and compound 5 in Table 1; CNTF and compound 6 in Table 1; CNTF and compound 7 in Table 1; CNTF and compound 8 in Table 1; CNTF and compound 9 in Table 1; CNTF and compound 10 in Table 1; CNTF and compound 11 in Table 1; CNTF and ONL1204; CNTF and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); CNTF and FAIM; CNTF and NOL3; CNTF and DcR1; CNTF and DcR2; CNTF and DcR3; CNTF and etanercept; CNTF and infliximab; CNTF and golimumab; CNTF and certolizumab; CNTF and adalimumab; CNTF and R1antTNF; CNTF and DMS5540; CNTF and TROS; CNTF and ATROSAB; CNTF and humanin; CNTF and humanin analog; CNTF and s14G-humanin; CNTF and MT P101; CNTF and elamipretide; CNTF and DNA; CNTF and RNA; CNTF and siRNA; CNTF and siRNA targeting FAS; CNTF and FAS siRNA sense; CNTF and negative siRNA sense; CNTF and siRNA targeting TNF-α; CNTF and NR58.3-14-3; CNTF and caspase 2; CNTF and caspase 3; CNTF and caspase 8; CNTF and caspase 9; CNTF protein derivatives and CNTF peptides; CNTF protein derivatives and peptide 21; protein derivative of CNTF and peptide 21; protein derivative of CNTF and rhCNTF; protein derivative of CNTF and NGF; protein derivative of CNTF and BDNF; protein derivative of CNTF and GDNF; protein derivative of CNTF and bicyclol; protein derivative of CNTF and FLIP; protein derivative of CNTF and MET12; protein derivative of CNTF and compound 1 in Table 1; protein derivative of CNTF and compound 2 in Table 1; protein derivative of CNTF and compound 3 in Table 1; protein derivative of CNTF and compound 4 in Table 1; protein derivative of CNTF and compound 5 in Table 1; protein derivative of CNTF and compound 6 in Table 1; protein derivative of CNTF and compound 7 in Table 1; protein derivative of CNTF and compound 8 in Table 1; protein derivative of CNTF and compound 9 in Table 1; protein derivative of CNTF and compound 10 in Table 1; protein derivative of CNTF and / or compound 11 in Table 1; protein derivative of CNTF and ONL1204; protein derivative of CNTF and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); CNTF protein derivative and FAIM; CNTF protein derivative and NOL3; CNTF protein derivative and DcR1; CNTF protein derivative and DcR2; CNTF protein derivative and DcR3; CNTF protein derivative and etanercept; CNTF protein derivative and infliximab; CNTF protein derivative and golimumab; CNTF protein derivative and certolizumab; CNTF protein derivative and adalimumab; CNTF protein derivative and R1antTNF; CNTF protein derivative and DMS5540; CNTF protein derivative and TROS; CNTF protein derivative and ATROSAB; C CNTF protein derivatives and humanin; CNTF protein derivatives and humanin analogs; CNTF protein derivatives and s14G-humanin; CNTF protein derivatives and MTP101; CNTF protein derivatives and elamipretide; CNTF protein derivatives and DNA; CNTF protein derivatives and RNA; CNTF protein derivatives and siRNA; CNTF protein derivatives and siRNA targeting FAS; CNTF protein derivatives and FAS siRNA sense; CNTF protein derivatives and negative siRNA sense; CNTF protein derivatives and siRNA targeting TNF-α; CNTF protein derivatives and NR58.3-14-3; CNTF protein derivative and caspase 2; CNTF protein derivative and caspase 3; CNTF protein derivative and caspase 8; CNTF protein derivative and caspase 9; CNTF peptide and peptide 21; CNTF peptide and rhCNTF; CNTF peptide and NGF; CNTF peptide and BDNF; CNTF peptide and GDNF; CNTF peptide and bicyclol; CNTF peptide and FLIP; CNTF peptide and MET12; CNTF peptide and compound 1 in Table 1; CNTF peptide and compound 2 in Table 1; CNTF peptide and compound 3 in Table 1; CNTF peptide and compound 4 in Table 1; CNTF peptide and compound 5 in Table 1; CNTF peptide and compound 6 in Table 1; CNTF peptide and compound 7 in Table 1; CNTF peptide and compound 8 in Table 1; CNTF peptide and compound 9 in Table 1; CNTF peptide and compound 10 in Table 1; CNTF peptide and / or compound 11 in Table 1; CNTF peptide and ONL1204; CNTF peptide and H. 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); CNTF peptide and FAIM; CNTF peptide and NOL3; CNTF peptide and DcR1; CNTF peptide and DcR2; CNTF peptide and DcR3; CNTF peptide and etanercept; CNTF peptide and infliximab; CNTF peptide and golimumab; CNTF peptide and certolizumab; CNTF peptide and adalimumab; CNTF peptide and R1antTNF; CNTF peptide and DMS5540; CNTF peptide and TROS; CNTF peptide and ATROSAB; CNTF peptide and Humanin; CNTF peptide and Humanin analog; CNTF peptide and s14G-Humanin; CNTF peptide and MTP101; CNTF peptide and elamipretide; CNTF peptide and DNA; CNTF peptide and RNA; CNTF peptide and siRNA; CNTF peptide and siRNA targeting FAS; CNTF peptide and FAS siRNA sense; CNTF peptide Peptide and negative siRNA sense; CNTF peptide and siRNA targeting TNF-α; CNTF peptide and NR58.3-14-3; CNTF peptide and caspase 2; CNTF peptide and caspase 3; CNTF peptide and caspase 8; CNTF peptide and caspase 9; peptide 21 and rhCNTF; peptide 21 and NGF; peptide 21 and BDNF; peptide 21 and GDNF; peptide 21 and bicyclol; peptide 21 and FLIP; peptide Peptide 21 and MET12; Peptide 21 and compound 1 in Table 1; Peptide 21 and compound 2 in Table 1; Peptide 21 and compound 3 in Table 1; Peptide 21 and compound 4 in Table 1; Peptide 21 and compound 5 in Table 1; Peptide 21 and compound 6 in Table 1; Peptide 21 and compound 7 in Table 1; Peptide 21 and compound 8 in Table 1; Peptide 21 and compound 9 in Table 1; Peptide 21 and compound 10 in Table 1; Peptide 21 and or compound 11 in Table 1; Peptide 21 and ONL1204; Peptide 21 and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); Peptide 21 and FAIM; Peptide 21 and NOL3; Peptide 21 and DcR1; Peptide 21 and DcR2; Peptide 21 and DcR3; Peptide 21 and etanercept; Peptide 21 and infliximab; Peptide 21 and golimumab; Peptide 21 and certolizumab; Peptide 21 and adalimumab; Peptide 21 and R1antTNF; Peptide 21 and DMS5540; Peptide 21 and TROS; Peptide 21 and ATROSAB; Peptide 21 and humanin; Peptide 21 and humanin analog; Peptide 21 and s14G-humanin; Peptide 21 and MTP101; Peptide 21 and elamipretide; Peptide 21 and DNA; Peptide 21 and RNA; Peptide 21 and siRNA; Peptide 21 and siRNA targeting FAS; Peptide 21 and FAS siRNA sense; Peptide 21 and negative siRNA NA sense; peptide 21 and siRNA targeting TNF-α; peptide 21 and NR58.3-14-3; peptide 21 and caspase 2; peptide 21 and caspase 3; peptide 21 and caspase 8; peptide 21 and caspase 9; rhCNTF and NGF; rhCNTF and BDNF; rhCNTF and GDNF; rhCNTF and bicyclol; rhCNTF and FLIP; rhCNTF and MET12; rhCNTF and compound 1 in Table 1; rhCNTF and compound 2 in Table 1; rhCNTF and compound 3 in Table 1; rhCNTF and compound 4 in Table 1; rhCNTF and compound 5 in Table 1; rhCNTF and compound 6 in Table 1; rhCNTF and compound 7 in Table 1; rhCNTF and compound 8 in Table 1; rhCNTF and compound 9 in Table 1; rhCNTF and compound 10 in Table 1; rhCNTF and or compound 11 in Table 1; rhCNTF and ONL1204; rhCNTF and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); rhCNTF and FAIM; rhCNTF and NOL3; rhCNTF and DcR1; rhCNTF and DcR2; rhCNTF and DcR3; rhCNTF and etanercept; rhCNTF and infliximab; rhCNTF and golimumab; rhCNTF and certolizumab; rhCNTF and adalimumab; rhCNTF and R1antTNF; rhCNTF and DMS5540; rhCNTF and TROS; rhCNTF and ATROSAB; rhCNTF and humanin; rhCNTF and humanin analog; rhCNTF and s14G-humanin; rhCNTF and MTP101; rhCNTF and elamipretide; rhCNTF and DNA; rhCNTF and RNA; rhCNTF and siRNA; rhCNTF and siRNA targeting FAS; rh CNTF and FAS siRNA sense; rhCNTF and negative siRNA sense; rhCNTF and siRNA targeting TNF-α; rhCNTF and NR58.3-14-3; rhCNTF and caspase 2; rhCNTF and caspase 3; rhCNTF and caspase 8; rhCNTF and caspase 9; NGF and BDNF; NGF and GDNF; NGF and bicyclol; NGF and FLIP; NGF and MET12; NGF and compound 1 in Table 1; NGF and compound 2 in Table 1; NGF and compound 3 in Table 1; NGF and compound 4 in Table 1; NGF and compound 5 in Table 1; NGF and compound 6 in Table 1; NGF and compound 7 in Table 1; NGF and compound 8 in Table 1; NGF and compound 9 in Table 1; NGF and compound 10 in Table 1; NGF and or compound 11 in Table 1; NGF and ONL1204; NGF and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); NGF and FAIM; NGF and NOL3; NGF and DcR1; NGF and DcR2; NGF and DcR3; NGF and etanercept; NGF and infliximab; NGF and golimumab; NGF and certolizumab; NGF and adalimumab; NGF and R1antTNF; NGF and DMS5540; NGF and TROS; NGF and ATROSAB; NGF and humanin; NGF and humanin analog; NGF and s14G-humanin; NGF and MTP101; NGF and elamipretide; NGF and DNA; NGF and RNA; NGF and siRNA; NGF and siRNA targeting FAS; NGF and FAS siRNA sense; NGF and negative siRNA sense; NGF and siRNA targeting TNF-α A; NGF and NR58.3-14-3; NGF and caspase 2; NGF and caspase 3; NGF and caspase 8; NGF and caspase 9; BDNF and GDNF; BDNF and bicyclol; BDNF and FLIP; BDNF and MET12; BDNF and compound 1 in Table 1; BDNF and compound 2 in Table 1; BDNF and compound 3 in Table 1; BDNF and compound 4 in Table 1; BDNF and compound 5 in Table 1; BDNF and compound 6 in Table 1; BDNF and compound 7 in Table 1; BDNF and compound 8 in Table 1; BDNF and compound 9 in Table 1; BDNF and compound 10 in Table 1; BDNF and compound 11 in Table 1; BDNF and ONL1204; BDNF and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); BDNF and FAIM; BDNF and NOL3; BDNF and DcR1; BDNF and DcR2; BDNF and DcR3; BDNF and etanercept; BDNF and infliximab; BDNF and golimumab; BDNF and certolizumab; BDNF and adalimumab; BDNF and R1antTNF; BDNF and DMS5540; BDNF and TROS; BDNF and ATROSAB; BDNF and humanin; BDNF and humanin analog; BDNF and s14G-humanin; BDNF and MTP101; BDNF and elamipretide; BDNF and DNA; BDNF and RNA; BDNF and siRNA; BDNF and siRNA targeting FAS; BDNF and FAS siRNA sense ;BDNF and negative siRNA sense;BDNF and siRNA targeting TNF-α;BDNF and NR58.3-14-3;BDNF and caspase 2;BDNF and caspase 3;BDNF and caspase 8;BDNF and caspase 9;GDNF and bicyclol;GDNF and FLIP;GDNF and MET12;GDNF and compound 1 in Table 1;GDNF and compound 2 in Table 1;GDNF and compound 3 in Table 1;GDNF and compound 4 in Table 1;GDNF and compound 5 in Table 1;GDNF and compound 6 in Table 1;GDNF and compound 7 in Table 1;GDNF and compound 8 in Table 1;GDNF and compound 9 in Table 1;GDNF and compound 10 in Table 1;GDNF and or compound 11 in Table 1;GDNF and ONL1204;GDNF and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); GDNF and FAIM; GDNF and NOL3; GDNF and DcR1; GDNF and DcR2; GDNF and DcR3; GDNF and etanercept; GDNF and infliximab; GDNF and golimumab; GDNF and certolizumab; GDNF and adalimumab; GDNF and R1antTNF; GDNF and DMS5540; GDNF and TROS; GDNF and ATROSAB; GDNF and humanin; GDNF and humanin analog; GDNF and s14G-humanin; GDNF and MTP101; GDNF and elamipretide; GDNF and DNA; GDNF and RNA; GDNF and siRNA; GDNF and FAS-targeted siRNA; GDNF and FAS-sense siRNA; GDNF and negative Active siRNA sense; siRNA targeting GDNF and TNF-α; GDNF and NR58.3-14-3; GDNF and caspase 2; GDNF and caspase 3; GDNF and caspase 8; GDNF and caspase 9; bicyclol and FLIP; bicyclol and MET12; bicyclol and compound 1 in Table 1; bicyclol and compound 2 in Table 1; bicyclol and compound 3 in Table 1; bicyclol and compound 4 in Table 1; bicyclol and compound 5 in Table 1; bicyclol and compound 6 in Table 1; bicyclol and compound 7 in Table 1; bicyclol and compound 8 in Table 1; bicyclol and compound 9 in Table 1; bicyclol and compound 10 in Table 1; bicyclol and or compound 11 in Table 1; bicyclol and ONL1204; bicyclol and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); bicyclol and FAIM; bicyclol and NOL3; bicyclol and DcR1; bicyclol and DcR2; bicyclol and DcR3; bicyclol and etanercept; bicyclol and infliximab; bicyclol and golimumab; bicyclol and certolizumab; bicyclol and adalimumab; bicyclol and R1antTNF; bicyclol and DMS5540; bicyclol and TROS; bicyclol and ATROSAB; bicyclol and humanin; bicyclol and humanin analog; bicyclol and s14G-humanin; bicyclol and MTP101; bicyclol and elamipretide; bicyclol and DNA; bicyclol and RNA; bicyclol and siRNA; bicyclol and FAS targeting siRNA targeting FAS; bicyclol and FAS siRNA sense; bicyclol and negative siRNA sense; bicyclol and siRNA targeting TNF-α; bicyclol and NR58.3-14-3; bicyclol and caspase 2; bicyclol and caspase 3; bicyclol and caspase 8; bicyclol and caspase 9; FLIP and MET12; FLIP and compound 1 in Table 1; FLIP and compound 2 in Table 1; FLIP and compound 3 in Table 1; FLIP and compound 4 in Table 1; FLIP and compound 5 in Table 1; FLIP and compound 6 in Table 1; FLIP and compound 7 in Table 1; FLIP and compound 8 in Table 1; FLIP and compound 9 in Table 1; FLIP and compound 10 in Table 1; FLIP and compound 11 in Table 1; FLIP and ONL1204; FLIP and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); FLIP and FAIM; FLIP and NOL3; FLIP and DcR1; FLIP and DcR2; FLIP and DcR3; FLIP and etanercept; FLIP and infliximab; FLIP and golimumab; FLIP and certolizumab; FLIP and adalimumab; FLIP and R1antTNF; FLIP and DMS5540; FLIP and TROS; FLIP and ATROSAB; FLIP and humanin; FLIP and humanin analog; FLIP and s14G-humanin; FLIP and MTP101; FLIP and elamipretide; FLIP and DNA; FLIP and RNA; FLIP and siRNA; FLIP and siRNA targeting FAS; FLIP and F AS siRNA sense; FLIP and negative siRNA sense; FLIP and siRNA targeting TNF-α; FLIP and NR58.3-14-3; FLIP and caspase 2; FLIP and caspase 3; FLIP and caspase 8; FLIP and caspase 9; MET12 and compound 1 in Table 1; MET12 and compound 2 in Table 1; MET12 and compound 3 in Table 1; MET12 and compound 4 in Table 1; MET12 and compound 5 in Table 1; MET12 and compound 6 in Table 1; MET12 and compound 7 in Table 1; MET12 and compound 8 in Table 1; MET12 and compound 9 in Table 1; MET12 and compound 10 in Table 1; MET12 and or compound 11 in Table 1; MET12 and ONL1204; MET12 and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); MET12 and FAIM; MET12 and NOL3; MET12 and DcR1; MET12 and DcR2; MET12 and DcR3; MET12 and etanercept; MET12 and infliximab; MET12 and golimumab; MET12 and certolizumab; MET12 and adalimumab; MET12 and R1antTNF; MET12 and DMS5540; MET12 and TROS; MET12 and ATROSAB; MET12 and humanin; MET12 and humanin analog; MET12 and s14G-humanin; MET12 and MTP101; MET12 and elamipretide; MET12 and DNA; MET12 and RNA; MET12 and siRNA; MET12 and siRNA targeting FAS; MET 12 and FAS siRNA sense; MET12 and negative siRNA sense; MET12 and siRNA targeting TNF-α; MET12 and NR58.3-14-3; MET12 and caspase 2; MET12 and caspase 3; MET12 and caspase 8; MET12 and caspase 9; Compound 1 in Table 1 and Compound 2 in Table 1; Compound 1 in Table 1 and Compound 3 in Table 1; Compound 1 in Table 1 and Compound 4 in Table 1; Compound 1 in Table 1 and Compound 5 in Table 1; Compound 1 in Table 1 and Compound 6 in Table 1; Compound 1 in Table 1 and Compound 7 in Table 1; Compound 1 in Table 1 and Compound 8 in Table 1; Compound 1 in Table 1 and Compound 9 in Table 1; Compound 1 in Table 1 and Compound 10 in Table 1; Compound 1 and / or Compound 11 in Table 1; Compound 1 in Table 1 and ONL1204; Compound 1 in Table 1 and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); Compound 1 in Table 1 and FAIM; Compound 1 in Table 1 and NOL3; Compound 1 in Table 1 and DcR1; Compound 1 in Table 1 and DcR2; Compound 1 in Table 1 and DcR3; Compound 1 in Table 1 and etanercept; Compound 1 in Table 1 and infliximab; Compound 1 in Table 1 and golimumab; Compound 1 in Table 1 and certolizumab; Compound 1 in Table 1 and adalimumab; Compound 1 in Table 1 and R1antTNF ;Compound 1 in Table 1 and DMS5540;Compound 1 in Table 1 and TROS;Compound 1 in Table 1 and ATROSAB;Compound 1 in Table 1 and Humanin;Compound 1 in Table 1 and Humanin analogs;Compound 1 in Table 1 and s14G-Humanin;Compound 1 in Table 1 and MTP101;Compound 1 in Table 1 and elamipretide;Compound 1 in Table 1 and DNA;Compound 1 in Table 1 and RNA;Compound 1 in Table 1 and siRNA;Compound 1 in Table 1 Compound 1 and siRNA targeting FAS; Compound 1 in Table 1 and FAS siRNA sense; Compound 1 in Table 1 and negative siRNA sense; Compound 1 in Table 1 and siRNA targeting TNF-α; Compound 1 in Table 1 and NR58.3-14-3; Compound 1 in Table 1 and caspase 2; Compound 1 in Table 1 and caspase 3; Compound 1 in Table 1 and caspase 8; Compound 1 in Table 1 and caspase 9; Compound 2 in Table 1 and compound 3 in Table 1; Compound 2 in Table 1 and compound 4 in Table 1; Compound 2 in Table 1 and compound 5 in Table 1; Compound 2 in Table 1 and compound 6 in Table 1; Compound 2 in Table 1 and compound 7 in Table 1; Compound 2 in Table 1 and compound 8 in Table 1; Compound 2 in Table 1 and compound 9 in Table 1; Compound 2 in Table 1 and compound 10 in Table 1; Compound 2 in Table 1 and / or compound 11 in Table 1; Compound 2 in Table 1 and ONL1204; Compound 2 in Table 1 and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); Compound 2 in Table 1 and FAIM; Compound 2 in Table 1 and NOL3; Compound 2 in Table 1 and DcR1; Compound 2 in Table 1 and DcR2; Compound 2 in Table 1 and DcR3; Compound 2 in Table 1 and etanercept; Compound 2 in Table 1 and infliximab; Compound 2 in Table 1 and golimumab; Compound 2 in Table 1 and certolizumab; Compound 2 in Table 1 and adalimumab; Compound 2 in Table 1 and R1an tTNF; Compound 2 in Table 1 and DMS5540; Compound 2 in Table 1 and TROS; Compound 2 in Table 1 and ATROSAB; Compound 2 in Table 1 and Humanin; Compound 2 in Table 1 and Humanin analogs; Compound 2 in Table 1 and s14G-Humanin; Compound 2 in Table 1 and MTP101; Compound 2 in Table 1 and elamipretide; Compound 2 in Table 1 and DNA; Compound 2 in Table 1 and RNA; Compound 2 in Table 1 and s iRNA; Compound 2 in Table 1 and siRNA targeting FAS; Compound 2 in Table 1 and FAS siRNA sense; Compound 2 in Table 1 and negative siRNA sense; Compound 2 in Table 1 and siRNA targeting TNF-α; Compound 2 in Table 1 and NR58.3-14-3; Compound 2 in Table 1 and caspase 2; Compound 2 in Table 1 and caspase 3; Compound 2 in Table 1 and caspase 8; Compound 2 in Table 1 and caspase 9; Compound 3 in Table 1 and compound 4 in Table 1; Compound 3 in Table 1 and compound 5 in Table 1; Compound 3 in Table 1 and compound 6 in Table 1; Compound 3 in Table 1 and compound 7 in Table 1; Compound 3 in Table 1 and compound 8 in Table 1; Compound 3 in Table 1 and compound 9 in Table 1; Compound 3 in Table 1 and compound 10 in Table 1; Compound 3 in Table 1 and / or compound 11 in Table 1; Compound 3 in Table 1 and ONL1204; Compound 3 in Table 1 and H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4); Compound 3 in Table 1 and FAIM; Compound 3 in Table 1 and NOL3; Compound 3 in Table 1 and DcR1; Compound 3 in Table 1 and DcR2; Compound 3 in Table 1 and DcR3; Compound 3 in Table 1 and etanercept ;Compound 3 in Table 1 and infliximab;Compound 3 in Table 1 and golimumab;Compound 3 in Table 1 and certolizumab;Compound 3 in Table 1 and adalimumab;Compound 3 in Table 1 and R1antTNF;Compound 3 in Table 1 and DMS5540;Compound 3 in Table 1 and TROS;Compound 3 in Table 1 and ATROSAB;Compound 3 in Table 1 and Humanin;Compound 3 in Table 1 and Humanin analogs;Compound 3 in Table 1 and s14G-Humanin;Compound 3 in Table 1 and MTP101;Compound 3 in Table 1 and elamipretide;Compound 3 in Table 1 and DNA;Compound 3 in Table 1 and RNA;Compound 3 in Table 1 and siRNA;Compound 3 in Table 1 and siRNA targeting FAS;Compound 3 in Table 1 and FA S siRNA sense; Compound 3 in Table 1 and negative siRNA sense; Compound 3 in Table 1 and siRNA targeting TNF-α; Compound 3 in Table 1 and NR58.3-14-3; Compound 3 in Table 1 and caspase 2; Compound 3 in Table 1 and caspase 3; Compound 3 in Table 1 and caspase 8; Compound 3 in Table 1 and caspase 9; Compound 4 in Table 1 and compound 5 in Table 1; Compound 4 in Table 1 and compound 6 in Table 1; Compound 4 in Table 1 and compound 7 in Table 1; Compound 4 in Table 1 and compound 8 in Table 1; Compound 4 in Table 1 and compound 9 in Table 1; Compound 4 in Table 1 and compound 10 in Table 1; Compound 4 in Table 1 and / or compound 11 in Table 1; Compound 4 in Table 1 and ONL1204; Compound 4 in Table 1 and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); Compound 4 in Table 1 and FAIM; Compound 4 in Table 1 and NOL3; Compound 4 in Table 1 and DcR1; Compound 4 in Table 1 and DcR2; Compound 4 in Table 1 and DcR3; Compound 4 in Table 1 and etanercept; Compound 4 in Table 1 and infliximab; Compound 4 in Table 1 and golimumab; Compound 4 in Table 1 and certolizumab; Compound 4 in Table 1 and adalimumab; Compound 4 in Table 1 and R1antTNF; Compound 4 in Table 1 and DMS5540; Compound 4 in Table 1 and TROS; Compound 4 in Table 1 and ATROSAB; Compound 4 in Table 1 and Humanin; Compound 4 in Table 1 and Humanin analog; Compound 4 in Table 1 and s14G-Humanin; Compound 4 in Table 1 and MTP101; Compound 4 in Table 1 and elamipretide; Compound 4 in Table 1 and DNA; Compounds in Table 1 Compound 4 and RNA; Compound 4 in Table 1 and siRNA; Compound 4 in Table 1 and siRNA targeting FAS; Compound 4 in Table 1 and FAS siRNA sense; Compound 4 in Table 1 and negative siRNA sense; Compound 4 in Table 1 and siRNA targeting TNF-α; Compound 4 in Table 1 and NR58.3-14-3; Compound 4 in Table 1 and caspase 2; Compound 4 in Table 1 and caspase 3; Compound 4 in Table 1 and caspase 8; Compound 4 in Table 1 and caspase 9; Compound 5 in Table 1 and compound 6 in Table 1; Compound 5 in Table 1 and compound 7 in Table 1; Compound 5 in Table 1 and compound 8 in Table 1; Compound 5 in Table 1 and compound 9 in Table 1; Compound 5 in Table 1 and compound 10 in Table 1; Compound 5 in Table 1 and / or compound 11 in Table 1; Compound 5 in Table 1 and ONL1204; Compound 5 in Table 1 and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); Compound 5 in Table 1 and FAIM; Compound 5 in Table 1 and NOL3; Compound 5 in Table 1 and DcR1; Compound 5 in Table 1 and DcR2; Compound 5 in Table 1 and DcR3; Compound 5 in Table 1 and etanercept; Compound 5 in Table 1 and infliximab; Compound 5 in Table 1 and golimumab; Compound 5 in Table 1 and certolizumab; Compound 5 in Table 1 and adalimumab; Compound 5 in Table 1 and R1antTNF; Compound 5 in Table 1 and DMS5540; Compound 5 in Table 1 and TROS; Compound 5 in Table 1 and ATROSAB; Compound 5 in Table 1 and Humanin; Compound 5 in Table 1 and Humanin analogs; Compound 5 in Table 1 and s14G-Humanin; Compound 5 in Table 1 and MTP101; Compound 5 in Table 1 and elamipretide; Compound 5 in Table 1 and D NA; Compound 5 in Table 1 and RNA; Compound 5 in Table 1 and siRNA; Compound 5 in Table 1 and siRNA targeting FAS; Compound 5 in Table 1 and FAS siRNA sense; Compound 5 in Table 1 and negative siRNA sense; Compound 5 in Table 1 and siRNA targeting TNF-α; Compound 5 in Table 1 and NR58.3-14-3; Compound 5 in Table 1 and caspase 2; Compound 5 in Table 1 and caspase 3; Compound 5 in Table 1 and caspase 8; Compound 5 in Table 1 and caspase 9; Compound 6 in Table 1 and compound 7 in Table 1; Compound 6 in Table 1 and compound 8 in Table 1; Compound 6 in Table 1 and compound 9 in Table 1; Compound 6 in Table 1 and compound 10 in Table 1; Compound 6 in Table 1 and / or compound 11 in Table 1; Compound 6 in Table 1 and ONL1204; Compound 6 in Table 1 and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); Compound 6 in Table 1 and FAIM; Compound 6 in Table 1 and NOL3; Compound 6 in Table 1 and DcR1; Compound 6 in Table 1 and DcR2; Compound 6 in Table 1 and DcR3; Compound 6 in Table 1 and etanercept; Compound 6 in Table 1 and infliximab; Compound 6 in Table 1 and golimumab; Compound 6 in Table 1 and certolizumab; Compound 6 in Table 1 and adalimumab; Compound 6 in Table 1 and R1antTNF; Compound 6 in Table 1 and DMS5540; Compound 6 in Table 1 and TROS; Compound 6 in Table 1 and ATROSAB; Compound 6 in Table 1 and Humanin; Compound 6 in Table 1 and Humanin analog; Compound 6 in Table 1 and s14G-Humanin; Compound 6 in Table 1 and MTP101; Compound 6 in Table 1 and elamipretide; Table Compound 6 in Table 1 and DNA; Compound 6 in Table 1 and RNA; Compound 6 in Table 1 and siRNA; Compound 6 in Table 1 and siRNA targeting FAS; Compound 6 in Table 1 and FAS siRNA sense; Compound 6 in Table 1 and negative siRNA sense; Compound 6 in Table 1 and siRNA targeting TNF-α; Compound 6 in Table 1 and NR58.3-14-3; Compound 6 in Table 1 and caspase 2; Compound 6 in Table 1 and caspase 3; Compound 6 in Table 1 and caspase 8; Compound 6 in Table 1 and caspase 9; Compound 7 in Table 1 and compound 8 in Table 1; Compound 7 in Table 1 and compound 9 in Table 1; Compound 7 in Table 1 and compound 10 in Table 1; Compound 7 in Table 1 and / or compound 11 in Table 1; Compound 7 in Table 1 and ONL1204; Compound 7 in Table 1 and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); Compound 7 in Table 1 and FAIM; Compound 7 in Table 1 and NOL3; Compound 7 in Table 1 and DcR1; Compound 7 in Table 1 and DcR2; Compound 7 in Table 1 and DcR3; Compound 7 in Table 1 and etanercept; Compound 7 in Table 1 and infliximab; Compound 7 in Table 1 and golimumab; Compound 7 in Table 1 and certolizumab; Compound 7 in Table 1 and adalimumab; Compound 7 in Table 1 and R1antTNF; Compound 7 in Table 1 and DMS5540; Compound 7 in Table 1 and TROS; Compound 7 in Table 1 and ATROSAB; Compound 7 in Table 1 and Humanin; Compound 7 in Table 1 and Humanin analog; Compound 7 in Table 1 and s14G-Humanin; Compound 7 in Table 1 and MTP101; Compound 7 in Table 1 and E Ramipretide; Compound 7 in Table 1 and DNA; Compound 7 in Table 1 and RNA; Compound 7 in Table 1 and siRNA; Compound 7 in Table 1 and siRNA targeting FAS; Compound 7 in Table 1 and FAS siRNA sense; Compound 7 in Table 1 and negative siRNA sense; Compound 7 in Table 1 and siRNA targeting TNF-α; Compound 7 in Table 1 and NR58.3-14-3; Compound 7 in Table 1 and caspase 2; Compound 7 in Table 1 and caspase 3; Compound 7 in Table 1 and caspase 8; Compound 7 in Table 1 and caspase 9; Compound 8 in Table 1 and compound 9 in Table 1; Compound 8 in Table 1 and compound 10 in Table 1; Compound 8 and / or compound 11 in Table 1; Compound 8 in Table 1 and ONL1204; Compound 8 in Table 1 and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); Compound 8 in Table 1 and FAIM; Compound 8 in Table 1 and NOL3; Compound 8 in Table 1 and DcR1; Compound 8 in Table 1 and DcR2; Compound 8 in Table 1 and DcR3; Compound 8 in Table 1 and etanercept; Compound 8 in Table 1 and infliximab; Compound 8 in Table 1 and golimumab; Compound 8 in Table 1 and certolizumab; Compound 8 in Table 1 and adalimumab; Compound 8 in Table 1 and R1antTNF; Compound 8 in Table 1 and DMS5540; Compound 8 in Table 1 and TROS; Compound 8 in Table 1 and ATROSAB; Compound 8 in Table 1 and Humanin; Compound 8 in Table 1 and Humanin analog; Compound 8 in Table 1 and s14G-Humanin; Compound 8 in Table 1 and MTP101; Compound 8 in Table 1 and elamipretide; Compound 8 in Table 1 and DNA; Compound 8 in Table 1 and RNA; Compound 8 in Table 1 and siRNA; Compound 8 in Table 1 and siRNA targeting FAS; Compound 8 in Table 1 and FAS siRNA sense; Compound 8 in Table 1 and negative siRNA sense; Compound 8 in Table 1 and siRNA targeting TNF-α; Compound 8 in Table 1 and NR58.3-14-3; Compound 8 in Table 1 and caspase 2; Compound 8 in Table 1 and caspase 3; Compound 8 in Table 1 and caspase 8; Compound 8 in Table 1 and caspase 9; Compound 9 in Table 1 and compound 10 in Table 1; Compound 9 and / or compound 11 in Table 1; Compound 9 in Table 1 and ONL1204; Compound 9 in Table 1 and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); Compound 9 in Table 1 and FAIM; Compound 9 in Table 1 and NOL3; Compound 9 in Table 1 and DcR1; Compound 9 in Table 1 and DcR2; Compound 9 in Table 1 and DcR3; Compound 9 in Table 1 and etanercept; Compound 9 in Table 1 and infliximab; Compound 9 in Table 1 and golimumab; Compound 9 in Table 1 and certolizumab; Compound 9 in Table 1 and adalimumab; Compound 9 in Table 1 and R1antTNF; Compound 9 in Table 1 and DMS5540; Compound 9 in Table 1 and TROS; Compound 9 in Table 1 and ATROSAB; Compound 9 in Table 1 and Humanin; Compound 9 in Table 1 and Humanin analogs; Compound 9 in Table 1 and s14G-Humanin; Compound 9 in Table 1 and M TP101; Compound 9 in Table 1 and elamipretide; Compound 9 in Table 1 and DNA; Compound 9 in Table 1 and RNA; Compound 9 in Table 1 and siRNA; Compound 9 in Table 1 and siRNA targeting FAS; Compound 9 in Table 1 and FAS siRNA sense; Compound 9 in Table 1 and negative siRNA sense; Compound 9 in Table 1 and siRNA targeting TNF-α; Compound 9 in Table 1 and NR58.3-14-3; Compound 9 in Table 1 and caspase 2; Compound 9 in Table 1 and caspase 3; Compound 9 in Table 1 and caspase 8; Compound 9 in Table 1 and caspase 9; Compound 10 and / or Compound 11 in Table 1; Compound 10 in Table 1 and ONL1204; Compound 10 in Table 1 and H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4); Compound 10 in Table 1 and FAIM; Compound 10 in Table 1 and NOL3; Compound 10 in Table 1 and DcR1; Compound 10 in Table 1 and DcR2; Compound 10 in Table 1 and DcR3; Compound 10 in Table 1 and etanercept; Compound 10 in Table 1 and infliximab; Compound 10 in Table 1 and golimumab; Compound 10 in Table 1 and certolizumab; Compound 10 in Table 1 and adalimumab; Compound 10 in Table 1 and R1antTNF; Compound 10 in Table 1 and DMS5540; Compound 10 in Table 1 and TROS; Compound 10 in Table 1 and ATROSAB; Compound 10 in Table 1 and Humanin; Compound 10 in Table 1 and Humanin analogs; Compound 10 in Table 1 and s14G-Humanin Mannin; Compound 10 in Table 1 and MTP101; Compound 10 in Table 1 and elamipretide; Compound 10 in Table 1 and DNA; Compound 10 in Table 1 and RNA; Compound 10 in Table 1 and siRNA; Compound 10 in Table 1 and siRNA targeting FAS; Compound 10 in Table 1 and FAS siRNA sense; Compound 10 in Table 1 and negative siRNA sense; Compound 10 in Table 1 and siRNA targeting TNF-α; Compound 10 in Table 1 and NR58.3-14-3; Compound 10 in Table 1 and caspase 2; Compound 10 in Table 1 and caspase 3; Compound 10 in Table 1 and caspase 8; Compound 10 in Table 1 and caspase 9; Compound 11 in Table 1 and ONL1204; Compound 11 in Table 1 and H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4); Compound 11 in Table 1 and FAIM; Compound 11 in Table 1 and NOL3; Compound 11 in Table 1 and DcR1; Compound 11 in Table 1 and DcR2; Compound 11 in Table 1 and DcR3; Compound 11 in Table 1 and etanercept; Compound 11 in Table 1 and infliximab; Compound 11 in Table 1 and golimumab; Compound 11 in Table 1 and certolizumab; Compound 11 in Table 1 and adalimumab; Compound 11 in Table 1 and R1antTNF; Compound 11 in Table 1 and DMS5540; Compound 11 in Table 1 and TROS; Compound 11 in Table 1 and ATROSAB; Compound 11 in Table 1 and Humanin; Compound 11 in Table 1 and Humanin analogs; Compound 11 in Table 1 and s14G-Humanin; Compound 11 in Table 1 and MTP101; Compound 11 in Table 1 and elamipretide; Compound 11 in Table 1 and DNA; Compound 11 in Table 1 and RNA; Compound 1 in Table 1 Compound 11 and siRNA; Compound 11 in Table 1 and siRNA targeting FAS; Compound 11 in Table 1 and FAS siRNA sense; Compound 11 in Table 1 and negative siRNA sense; Compound 11 in Table 1 and siRNA targeting TNF-α; Compound 11 in Table 1 and NR58.3-14-3; Compound 11 in Table 1 and caspase 2; Compound 11 in Table 1 and caspase 3; Compound 11 in Table 1 and caspase 8; Compound 11 in Table 1 and caspase 9; ONL1204 and H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4); ONL1204 and FAIM; ONL1204 and NOL3; ONL1204 and DcR1; ONL1204 and DcR2; ONL1204 and DcR3; ONL1204 and etanercept; ONL1204 and infliximab; ONL1204 and golimumab; ONL1204 and certolizumab; ONL1204 and adalimumab; ONL1204 and R1antTNF; ONL1204 and DMS5540; ONL1204 and TROS; ONL1204 and ATROSAB; ONL1204 and Humanin; ONL1204 and Humanin analog; ONL12 04 and s14G-humanin; ONL1204 and MTP101; ONL1204 and elamipretide; ONL1204 and DNA; ONL1204 and RNA; ONL1204 and siRNA; ONL1204 and siRNA targeting FAS; ONL1204 and FAS siRNA sense; ONL1204 and negative siRNA sense; ONL1204 and siRNA targeting TNF-α; ONL1204 and NR58.3-14-3; ONL1204 and caspase 2; ONL1204 and caspase 3; ONL1204 and caspase 8; ONL1204 and caspase 9; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and FAIM;H60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and NOL3;H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and DcR1;H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and DcR2;H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and DcR3;H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and etanercept; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) with infliximab; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) with golimumab; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) with certolizumab; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) with adalimumab; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and R1antTNF;H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and DMS5540; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and TROS;H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and ATROSAB;H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and Humanin; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and Humanin analog; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and s14G-humanin; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and MTP101;H 60 HIYLGATNYIY71 -NH2 (SEQ ID NO: 4) and elamipretide; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and DNA; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and RNA; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and siRNA; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and siRNA targeting FAS; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and FAS siRNA sense; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and negative siRNA sense; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and siRNA targeting TNF-α; H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and NR58.3-14-3;H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and caspase 2;H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and caspase 3;H 60 HIYLGATNYIY 71 -NH2 (SEQ ID NO: 4) and caspase 8;H 60 HIYLGATNYIY 71-NH2 (SEQ ID NO: 4) and caspase-9; FAIM and NOL3; FAIM and DcR1; FAIM and DcR2; FAIM and DcR3; FAIM and etanercept; FAIM and infliximab; FAIM and golimumab; FAIM and certolizumab; FAIM and adalimumab; FAIM and R1antTNF; FAIM and DMS5540; FAIM and TROS; FAIM and ATROSAB; FAIM and humanin; FAIM and humanin analog; FAIM and s14G-humanin; FAIM and MTP101; FAIM and elamipretide; FAIM and DNA; FAIM and RNA; FAIM and siRNA; FAIM and siRNA targeting FAS; FAIM and FAS siRNA sense; FAIM and negative siRNA sense; FAIM and siRNA targeting TNF-α; FAIM and NR58.3-14-3; FAIM and caspases Caspase-2; FAIM and caspase-3; FAIM and caspase-8; FAIM and caspase-9; NOL3 and DcR1; NOL3 and DcR2; NOL3 and DcR3; NOL3 and etanercept; NOL3 and infliximab; NOL3 and golimumab; NOL3 and certolizumab; NOL3 and adalimumab; NOL3 and R1antTNF; NOL3 and DMS5540; NOL3 and TROS; NOL3 and ATROSAB; NOL3 and humanin; NOL3 and humanin analog; NOL3 and s14G-humanin; NOL3 and MTP101; NOL3 and elamipretide; NOL3 and DNA; NOL3 and RNA; NOL3 and siRNA; NOL3 and siRNA targeting FAS; NOL3 and FAS siRNA sense; NOL3 and negative siRNA sense; NOL3 and siRNA targeting TNF-α; NOL3 and NR58.3-14-3; NOL3 and caspase-2; NOL3 and caspase-3; NOL3 and caspase-8; NOL3 and caspase-9; DcR1 and DcR2; DcR1 and DcR3; DcR1 and etanercept; DcR1 and infliximab; DcR1 and golimumab; DcR1 and certolizumab; DcR1 and adalimumab; DcR1 and R1antTNF; DcR1 and DMS5540; DcR1 and TROS; DcR1 and ATRO SAB; DcR1 and humanin; DcR1 and humanin analog; DcR1 and s14G-humanin; DcR1 and MTP101; DcR1 and elamipretide; DcR1 and DNA; DcR1 and RNA; DcR1 and siRNA; DcR1 and siRNA targeting FAS; DcR1 and FAS siRNA sense; DcR1 and negative siRNA sense; DcR1 and siRNA targeting TNF-α; DcR1 and NR58.3-14-3; DcR1 and caspase-2; DcR1 and caspase-3; DcR1 and caspase-8; DcR1 and caspase-9; DcR2 and DcR3; DcR2 and etanercept; DcR2 and infliximab; DcR2 and golimumab; DcR2 and certolizumab; DcR2 and adalimumab; DcR2 and R1antTNF; DcR2 and DMS5540; DcR2 and TROS; DcR2 and ATROSAB; D DcR2 and humanin; DcR2 and humanin analog; DcR2 and s14G-humanin; DcR2 and MTP101; DcR2 and elamipretide; DcR2 and DNA; DcR2 and RNA; DcR2 and siRNA; DcR2 and siRNA targeting FAS; DcR2 and FAS siRNA sense; DcR2 and negative siRNA sense; DcR2 and siRNA targeting TNF-α; DcR2 and NR58.3-14-3; DcR2 and caspase-2; DcR2 and caspase-3; DcR2 and caspase-8; DcR2 and caspase-9; DcR3 and etanercept; DcR3 and infliximab; DcR3 and golimumab; DcR3 and certolizumab; DcR3 and adalimumab; DcR3 and R1antTNF; DcR3 and DMS5540; DcR3 and TROS; DcR3 and ATROSAB; DcR3 and humanin; DcR3 and human DcR3 and s14G-humanin analogs; DcR3 and s14G-humanin; DcR3 and MTP101; DcR3 and elamipretide; DcR3 and DNA; DcR3 and RNA; DcR3 and siRNA; DcR3 and siRNA targeting FAS; DcR3 and FAS siRNA sense; DcR3 and negative siRNA sense; DcR3 and siRNA targeting TNF-α; DcR3 and NR58.3-14-3; DcR3 and caspase 2; DcR3 and caspase 3 DcR3 and caspase-3; DcR3 and caspase-8; DcR3 and caspase-9; etanercept and infliximab; etanercept and golimumab; etanercept and certolizumab; etanercept and adalimumab; etanercept and R1antTNF; etanercept and DMS5540; etanercept and TROS; etanercept and ATROSAB; etanercept and humanin; etanercept and humanin analogs; etanercept Etanercept and s14G-humanin; etanercept and MTP101; etanercept and elamipretide; etanercept and DNA; etanercept and RNA; etanercept and siRNA; etanercept and FAS-targeting siRNA; etanercept and FAS-sense siRNA; etanercept and negative siRNA sense; etanercept and TNF-α-targeting siRNA; etanercept and NR58.3-14-3; etanercept and caspase 2; etanercept and caspase 3; etanercept and caspase 8; etanercept and caspase 9; infliximab and golimumab; infliximab and certolizumab; infliximab and adalimumab; infliximab and R1antTNF; infliximab and DMS5540; infliximab and TROS; infliximab and ATROSAB; infliximab and Humanin; infliximab and Humanin analogs; infliximab and s14G-Humanin; infliximab and MTP101; infliximab and elamipretide; infliximab and DNA; infliximab and RNA; infliximab and siRNA; infliximab and siRNA targeting FAS; Infliximab. Infliximab and FAS siRNA sense; infliximab and negative siRNA sense; infliximab and siRNA targeting TNF-α; infliximab and NR58.3-14-3; infliximab and caspase 2; infliximab and caspase 3; infliximab and caspase 8; infliximab and caspase 9; golimumab and certolizumab; golimumab and adalimumab; golimumab and R1antTNF; golimumab and DMS5540; golimumab and TROS; golimumab and ATROSAB; golimumab and Humanin; golimumab and Humanin analog; golimumab and s14G-Humanin; golimumab and MTP101; golimumab and elamipretide; golimumab and DNA; golimumab and RNA; golimumab and siRNA; golimumab and siRNA targeting FAS; golimumab and FAS siRNA sense; golimumab and negative siRNA sense; Golimumab and siRNA targeting TNF-α; golimumab and NR58.3-14-3; golimumab and caspase 2; golimumab and caspase 3; golimumab and caspase 8; golimumab and caspase 9; certolizumab and adalimumab; certolizumab and R1antTNF; certolizumab and DMS5540; certolizumab and TROS; certolizumab and ATROSAB; certolizumab and Humanin; certolizumab and Humanin Humanin analogs; certolizumab and s14G-humanin; certolizumab and MTP101; certolizumab and elamipretide; certolizumab and DNA; certolizumab and RNA; certolizumab and siRNA; certolizumab and siRNA targeting FAS; certolizumab and FAS siRNA sense; certolizumab and negative siRNA sense; certolizumab and siRNA targeting TNF-α; certolizumab and NR58.3-14-3; certolizumab and caspase 2; certolizumab and caspase 3; certolizumab and caspase 8; certolizumab and caspase 9; adalimumab and R1antTNF; adalimumab and DMS5540; adalimumab and TROS; adalimumab and ATROSAB; adalimumab and Humanin; adalimumab and Humanin analogs; adalimumab and s14G-Humanin Mannin; adalimumab and MTP101; adalimumab and elamipretide; adalimumab and DNA; adalimumab and RNA; adalimumab and siRNA; adalimumab and siRNA targeting FAS; adalimumab and FAS siRNA sense; adalimumab and negative siRNA sense; adalimumab and siRNA targeting TNF-α; adalimumab and NR58.3-14-3 ; Adalimumab and caspase 2; Adalimumab and caspase 3; Adalimumab and caspase 8; Adalimumab and caspase 9; R1antTNF and DMS5540; R1antTNF and TROS; R1antTNF and ATROSAB; R1antTNF and humanin; R1antTNF and humanin analog; R1antTNF and s14G-humanin; R1antTNF and MTP101; R1antTNF and elamipretide; R1antTNF and DNA; R1antTNF and RNA; R1antTNF and siRNA; R1antTNF and siRNA targeting FAS; R1antTNF and FAS siRNA sense; R1antTNF and negative siRNA sense; R1antTNF and siRNA targeting TNF-α; R1antTNF and NR58.3-14-3; R1antTNF and caspase 2; R1antTNF and caspase 3; R1antTNF and caspase 8; R1antTNF and caspase 9; DMS5540 and TROS; DMS5540 and ATROSAB; DMS5540 and humanin; DMS5540 and humanin analog; DMS5540 and s14G-humanin; DMS5540 and MTP101; DMS5540 and elamipretide; DMS5540 and DNA; DMS5540 and RNA; DMS5540 and s iRNA; DMS5540 and siRNA targeting FAS; DMS5540 and FAS siRNA sense; DMS5540 and negative siRNA sense; DMS5540 and siRNA targeting TNF-α; DMS5540 and NR58.3-14-3; DMS5540 and caspase 2; DMS5540 and caspase 3; DMS5540 and caspase 8; DMS5540 and caspase 9; TROS and ATROSAB; TROS and humanin; TROS and humanin analog; TRO S and s14G-humanin; TROS and MTP101; TROS and elamipretide; TROS and DNA; TROS and RNA; TROS and siRNA; TROS and siRNA targeting FAS; TROS and FAS siRNA sense; TROS and negative siRNA sense; TROS and siRNA targeting TNF-α; TROS and NR58.3-14-3; TROS and caspase-2; TROS and caspase-3; TROS and caspase-8; TROS and caspase-9; ATROSAB and Humanin; ATROSAB and Humanin analog; ATROSAB and s14G-Humanin; ATROSAB and MTP101; ATROSAB and elamipretide; ATROSAB and DNA; ATROSAB and RNA; ATROSAB and siRNA; ATROSAB and siRNA targeting FAS; ATROSAB and FAS siRNA sense; ATROSAB and negative siRNA sense; ATROSAB and siRNA targeting TNF-α; ATROSAB and NR58.3-14-3; ATROSAB and caspase-2; ATROSAB and caspase-3; ATROSAB and caspase-8; ATROSAB and caspase-9; Humanin and humanin analogs; Humanin and s14G-Humanin; Humanin and MTP101; Humanin and elamipretide; Humanin and DNA; Humanin and RNA; Humanin and siRNA; Humanin and siRNA targeting FAS; Humanin and FAS siRNA sense Humanin and negative-sense siRNA; Humanin and siRNA targeting TNF-α; Humanin and NR58.3-14-3; Humanin and caspase-2; Humanin and caspase-3; Humanin and caspase-8; Humanin and caspase-9; Humanin analogs and s14G-Humanin; Humanin analogs and MTP101; Humanin analogs and elamipretide; Humanin analogs and DNA; Humanin analogs and RNA; Humanin Humanin analogs and siRNA; Humanin analogs and siRNA targeting FAS; Humanin analogs and FAS siRNA sense; Humanin analogs and negative siRNA sense; Humanin analogs and siRNA targeting TNF-α; Humanin analogs and NR58.3-14-3; Humanin analogs and caspase 2; Humanin analogs and caspase 3; Humanin analogs and caspase 8; Humanin analogs and caspase 9; s14G -Humanin and MTP101; s14G-Humanin and elamipretide; s14G-Humanin and DNA; s14G-Humanin and RNA; s14G-Humanin and siRNA; s14G-Humanin and siRNA targeting FAS; s14G-Humanin and FAS siRNA sense; s14G-Humanin and negative siRNA sense; s14G-Humanin and siRNA targeting TNF-α; s14G-Humanin and NR58.3-14-3; s14G-humanin and caspase 2; s14G-humanin and caspase 3; s14G-humanin and caspase 8; s14G-humanin and caspase 9; MTP101 and elamipretide; MTP101 and DNA; MTP101 and RNA; MTP101 and siRNA; MTP101 and siRNA targeting FAS; MTP101 and FAS siRNA sense; MTP101 and negative siRNA sense; MTP101 and siRNA targeting TNF-α; MTP 101 and NR58.3-14-3; MTP101 and caspase 2; MTP101 and caspase 3; MTP101 and caspase 8; MTP101 and caspase 9; elamipretide and DNA; elamipretide and RNA; elamipretide and siRNA; elamipretide and siRNA targeting FAS; elamipretide and FAS siRNA sense; elamipretide and negative siRNA sense; elamipretide and siRNA targeting TNF-α; elamipretide and NR58.3-14-3; elamipretide Elamipretide and caspase-2; elamipretide and caspase-3; elamipretide and caspase-8; elamipretide and caspase-9; DNA and RNA; DNA and siRNA; DNA and siRNA targeting FAS; DNA and FAS siRNA sense; DNA and negative siRNA sense; DNA and siRNA targeting TNF-α; DNA and NR58.3-14-3; DNA and caspase-2; DNA and caspase-3; DNA and caspase-8; DNA and caspase-9; RNA and siRNA; RNA and siRNA targeting FAS; RNA and FAS siRNA sense; RNA and negative siRNA sense; RNA and siRNA targeting TNF-α; RNA and NR58.3-14-3; RNA and caspase-2; RNA and caspase-3; RNA and caspase-8; RNA and caspase-9; siRNA and siRNA targeting FAS; siRNA and FAS siRNA sense; siRNA and negative siRNA sense; siRNA and siRNA targeting TNF-α; siRNA and NR58.3-14-3; siRNA and caspase-2; siRNA and caspase-3; siRNA and caspase-8; siRNA and caspase-9; siRNA targeting FAS and FAS siRNA sense; siRNA targeting FAS and negative siRNA sense; siRNA targeting FAS and siRNA targeting TNF-α; siRNA targeting FAS and NR58.3-14-3; siRNA targeting FAS and caspase-2; siRNA targeting FAS and caspase-3; siRNA targeting FAS and caspase-8; siRNA targeting FAS and caspase-9; FAS siRNA sense and negative siRNA sense; FAS siRNA sense and siRNA targeting TNF-α; FAS siRNA sense and NR58.3-14-3; FAS siRNA sense and caspase-2; FAS siRNA sense and caspase-3; FAS siRNA sense and caspase-8; FAS siRNA sense and caspase-9; negative siRNA sense and TNF-α negative siRNA sense and NR58.3-14-3; negative siRNA sense and caspase 2; negative siRNA sense and caspase 3; negative siRNA sense and caspase 8; negative siRNA sense and caspase 9; siRNA targeting TNF-α and NR58.3-14-3; siRNA targeting TNF-α and caspase 2; siRNA targeting TNF-α and caspase 3; siRNA targeting TNF-α and caspase 8; T These include NF-α-targeting siRNA and caspase-9; NR58.3-14-3 and caspase-2; NR58.3-14-3 and caspase-3; NR58.3-14-3 and caspase-8; NR58.3-14-3 and caspase-9; caspase-2 and caspase-3; caspase-2 and caspase-8; caspase-2 and caspase-9; caspase-3 and caspase-8; caspase-3 and caspase-9; caspase-8 and caspase-9; or MET12 (SEQ ID NO: 3) and peptide 6 (SEQ ID NO: 1).

[0037] With respect to any related structural representation, such as Formula 1, I, 2, D, E, or F, Neu-H is a neurotrophic agent, such as those described above.

[0038] With respect to any related structural representation, such as Formula 1, A, G, H, J, or K, FAS-H is a FAS / FASL inhibitor, such as those FAS / FASL inhibitors described above.

[0039] With respect to any related structural representation, such as formula I, B, G, M, N, or O, TNF-H is a TNF-α / TNFR inhibitor, such as the TNF-α / TNFR inhibitors described above.

[0040] With respect to Formula 2, any related structural representation such as H, M, P, Q, or R, Mit-H is a mitochondrial peptide such as those described above.

[0041] With respect to any related structural representation, such as formula A, B, D, P, S, or T, Nuc-H is an oligonucleotide, such as the oligonucleotides described above.

[0042] With respect to any related structural representation, such as formula E, J, N, Q, S, or U, CK-H is a chemokine inhibitor, such as those described above.

[0043] With respect to related structural representations such as formula F, K, O, R, T, or U, CAS-H is a cysteine-aspartic protease inhibitor, such as the cysteine-aspartic proteases described above.

[0044] For representations of any related structure, such as 1, I, 2, 3, 4, 5, 6, 7, A, B, C, C1, D, E, F, G, H, J, K, M, N, O, P, Q, R, S, T, U, II, IID, 3D, 4D, 5D, 6D, or 7D (formulas C, II, IID, 3-7, and 3D-7D are shown below), i.e., containing L, L is a group of the empirical formula C a H b O c N d or C a H b O c is a linking group represented by the formula:

[0045] For any L, a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, a is 1-5, 5-10, 10-15, 15-20, 1-10, or 10-20.

[0046] For any L, b is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, or 43. In some embodiments, b is 1 to 10, 10 to 20, 20 to 30, 30 to 40, 40 to 43, 1 to 15, 15 to 30, or 30 to 43.

[0047] For any L, c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, c is 0-2, 2-4, 4-6, 6-8, 8-10, 0-3, 3-6, or 6-10.

[0048] For any L, d is 0, 1, or 2. In some embodiments, d is 0. In some embodiments, d is 1. In some embodiments, d is 2.

[0049] In some embodiments, L is a group of formula L-1, L-2, L-3, L-4, L-5, L-6, L-7, or L-8: [ka] [ka] It can be expressed as:

[0050] For any related structural representation of formula L-1, L-2, L-3, L-4, L-5, L-6, L-7, or L-8, L 1 is the empirical formula C e H f O g N hor C e H f O g It can be expressed as:

[0051] Any L 1 In some embodiments, e is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18. In some embodiments, e is 1 to 5, 5 to 10, 10 to 15, 15 to 20, 1 to 10, or 10 to 18.

[0052] Any L 1 In some embodiments, f is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or 38. In some embodiments, f is 1 to 10, 10 to 20, 20 to 30, 30 to 38, 1 to 15, 15 to 30, or 30 to 38.

[0053] Any L 1 In some embodiments, g is 0, 1, 2, 3, 4, 5, 6, 7, or 8. In some embodiments, g is 0 to 2, 2 to 4, 4 to 6, 6 to 8, 0 to 3, 3 to 6, or 6 to 8.

[0054] Any L 1 In some embodiments, h is 0. In some embodiments, h is 1. In some embodiments, h is 2.

[0055] With respect to any related structural representations such as formula L-1, L-2, L-3, L-4, L-5, L-6, L-7, or L-8, in some embodiments, L 1 teeth, -(CH2) i -(OCH2CH2) j -O-(CH2) k - [Formula L 1 -1], -(CH2) i -(OCH2CH2) j-O-CONH-(CH2) k - [Formula L 1 -2], -(C i H 2i )-(OCH2CH2) j -O-(C k H 2k )- [formula L 1 -3], or -( C i H 2i )-(OCH2CH2) j -O-CONH-(C k H 2k )- [formula L 1 -4] may be.

[0056] formula L 1 -1, L 1 -2, L 1 -3, or L 1 For any related structural representation such as -4, i is 0, 1, 2, 3, or 4.

[0057] formula L 1 -1, L 1 -2, L 1 -3, or L 1 For any related structural representation such as -4, j is 0, 1, 2, 3, 4, or 5.

[0058] For any related structural representation such as formula L1-1, L1-2, L1-3, or L1-4, k is 0, 1, 2, 3, or 4.

[0059] A sustained delivery component is a part of a drug delivery system that allows a drug to remain in the body for a sustained period of time, e.g., longer than the time it takes for the drug to be metabolized or exit the body. Typically, the sustained delivery component is an implant, such as a solid implant, that functions by encapsulating or otherwise trapping the drug within the implant. If the implant is biodegradable or bioerodible, the drug can be released as the implant biodegrades or bioerodes. The implant may also be porous so that the drug diffuses out of the implant over a period of time. Biodegradable or bioerodible implants may be porous or non-porous. Typically, non-biodegradable or non-bioerodible implants are porous, and the drug is released by diffusion. However, other mechanisms, such as an osmotic pump, may also be employed.

[0060] The agent may be physically entrapped in the sustained delivery component and / or may be covalently bound to a molecule that is part of the sustained delivery component.

[0061] Typical examples of biodegradable materials for porous or non-porous biodegradable implants generally include silica-based materials and organic biodegradable materials such as polymers including poly(D,L-lactic acid) (PLA) and poly(D,L-lactic-co-glycolic acid) (PLGA), polyesteramide (PEA, DSM Chemical), and polycaprolactone (PCL); hydrogels such as polyvinyl alcohol (PVA), PEG amine, PEG-N-hydroxysuccinamide ester (Ocular Therapeutix, etc.); collagen-based materials (Euclid systems); or combinations thereof.

[0062] There are many suitable silica-based sustained delivery compositions.

[0063] One type of silica-based sustained-release component includes a silica hydrogel composite obtained by mixing silica particles containing an encapsulated drug with a silica sol, and the resulting hydrogel composite is shear-thinning. This type of delivery system is an injectable, all-silica-based microparticle-silica hydrogel controlled-release system that significantly reduces burst release of different types of encapsulated therapeutic and biologically active agents. A detailed description of this type of silica-based sustained-release component and its method of manufacture can be found in U.S. Patent No. 9,949,922 to Jokinen et al., issued April 24, 2018, the entire contents of which are incorporated herein by reference.

[0064] Another type of silica-based sustained delivery component includes drug-containing flowable silica compositions and gel compositions obtained by a method for producing a flowable silica composition that includes a sol-gel transition followed by redispersion. The redispersion involves adding a liquid to the gel formed by the sol-gel transition after the gel point of the sol-gel transition is reached, within a sufficiently short time after the gel point is reached, such that the gel and liquid are mixed together to form a viscoelastically homogeneous flowable silica composition that is injectable directly through a thin 22G needle or with brief agitation of less than 30 seconds, and remains injectable. The flowable, injectable sustained delivery silica composition can enhance the stability and maintain activity of the encapsulated therapeutic agent. A detailed description of this type of silica-based sustained delivery component and its method of production can be found in U.S. Patent Application No. 20140057996 to Jokinen et al., published February 27, 2014, the entire contents of which are incorporated herein by reference.

[0065] Another type of silica-based sustained delivery component includes a composition comprising a bioerodible porous silicon-based carrier material carrying a drug and at least one amorphous sugar, optionally further comprising a crystallization inhibitor. These delivery systems involve loading a biomolecule into the pores of the silica carrier material, resulting in stabilization of the biomolecule. However, these systems may also be used for small molecule therapeutic compounds. A detailed description of this type of silica-based sustained delivery component and its manufacturing method can be found in U.S. Patent No. 9,603,801 to Barnett et al., issued March 28, 2017, the entire contents of which are incorporated herein by reference.

[0066] Another type of silica-based sustained delivery component includes bioerodible devices, such as implants, for controlled drug delivery. These devices include porous silicon-based carrier materials impregnated with or loaded with a drug. These particular silicon carrier materials contain at least one large molecule therapeutic agent disposed within the pores of the carrier material. Loading the therapeutic large molecule into the pores of the carrier material is believed to stabilize the large molecule. In many embodiments, the large molecule is a protein, the pores have an average size of about 15 nm to about 40 nm, and the protein has a molecular weight of about 100,000 amu to about 200,000 amu. A detailed description of this type of silica-based sustained delivery component and methods for its manufacture can be found in U.S. Pat. No. 9,808,421 to Ashton et al., issued November 7, 2017, U.S. Pat. No. 9,333,173 to Ashton et al., issued May 10, 2016, and U.S. Patent Publication No. 20140271764 to Ashton et al., published September 28, 2014, the entire contents of all of which are incorporated herein by reference.

[0067] The sustained delivery component may be about 10 μg to 100 mg, about 10 to 20 μg, about 20 to 30 μg, about 30 to 40 μg, about 40 to 50 μg, about 50 to 60 μg, about 60 to 70 μg, about 70 to 80 μg, about 80 to 90 μg, about 90 to 100 μg, about 100 to 200 μg, about 200 to 300 μg, about 300 to 400 μg, about 400 to 500 μg, about 500 to 600 μg, about 600 to 700 μg, about 700 to 800 μg, about 800 to 900 μg, about 90 0-1,000μg, approximately 1-2mg, approximately 2-3mg, approximately 3-4mg, approximately 4-5mg, approximately 5-6mg, approximately 6-7mg, approximately 7-8mg, approximately 8-9mg, approximately 9-10mg, approximately 10-20mg, approximately 20-30mg, approximately 30-40mg, approximately 40-50mg, approximately 50-60mg, approximately 60-70mg, approximately 70-80mg, approximately 80-90mg, approximately 90-100mg, approximately 100-200mg, approximately 200-300mg, approximately 300-400mg, approximately 400- 500mg, about 500-600mg, about 600-700mg, about 700-800mg, about 800-900mg, about 900-1,000mg, about 1-2g, about 2-3g, about 3-4g, about 4-5g, about 5-6g, about 6-7 g, about 7-8g, about 8-9g, about 9-10g, about 10-20g, about 20-30g, about 30-40g, about 40-50g, about 50-60g, about 60-70g, about 70-80g, about 80-90g, about 90-100g, about 10 The drug may have any suitable mass, such as 0 to 200 g, about 200 to 300 g, about 300 to 400 g, about 400 to 500 g, about 500 to 600 g, about 600 to 700 g, about 700 to 800 g, about 800 to 900 g, about 900 to 1,000 g, about 10 to 100 μg, about 100 to 1,000 μg, about 1 to 10 mg, about 10 to 100 mg, about 100 to 1,000 mg, about 1 to 10 g, about 10 to 100 g, or about 100 to 1,000 g. The above ranges of about 1 g or less, or about 100 mg or less, may be of interest for drug delivery systems delivered onto or into the eye.

[0068] The sustained delivery component may be any suitable percentage of the implant, such as about 1-99% by weight, about 1-10% by weight, about 10-20% by weight, about 20-30% by weight, about 30-40% by weight, about 40-50% by weight, about 50-60% by weight, about 60-70% by weight, about 70-80% by weight, about 80-90% by weight, about 90-99% by weight, about 1-30% by weight, about 30-65% by weight, about 65-99% by weight, about 1-50% by weight, or about 50-99% by weight.

[0069] The drug delivery system may be administered in a range of dosages, including about 10 μg to 100 mg, about 10 to 20 μg, about 20 to 30 μg, about 30 to 40 μg, about 40 to 50 μg, about 50 to 60 μg, about 60 to 70 μg, about 70 to 80 μg, about 80 to 90 μg, about 90 to 100 μg, about 100 to 200 μg, about 200 to 300 μg, about 300 to 400 μg, about 400 to 500 μg, about 500 to 600 μg, about 600 to 700 μg, about 700 to 800 μg, about 800 to 900 μg, and about 900-1,000μg, approximately 1-2mg, approximately 2-3mg, approximately 3-4mg, approximately 4-5mg, approximately 5-6mg, approximately 6-7mg, approximately 7-8mg, approximately 8-9mg, approximately 9-10mg, approximately 10-20mg, approximately 20-30mg, approximately 30-40mg, approximately 40-50mg, approximately 50-60mg, approximately 60-70mg, approximately 70-80mg, approximately 80-90mg, approximately 90-100mg, approximately 100-200mg, approximately 200-300mg, approximately 300-400mg, approximately 40 0~500mg, approx. 500~600mg, approx. 600~700mg, approx. 700~800mg, approx. 800~900mg, approx. 900~1,000mg, approx. 1~2g, approx. 2~3g, approx. 3~4g, approx. 4~5g, approx. 5~6g, approx. 6 ~7g, approximately 7~8g, approximately 8~9g, approximately 9~10g, approximately 10~20g, approximately 20~30g, approximately 30~40g, approximately 40~50g, approximately 50~60g, approximately 60~70g, approximately 70~80g, approximately 80~90g, approximately 90~100g, approx. The dosage may be any suitable size, such as 100-200 g, about 200-300 g, about 300-400 g, about 400-500 g, about 500-600 g, about 600-700 g, about 700-800 g, about 800-900 g, about 900-1,000 g, about 10-100 μg, about 100-1,000 μg, about 1-10 mg, about 10-100 mg, about 100-1,000 mg, about 1-10 g, about 10-100 g, or about 100-1,000 g. The above ranges of about 1 g or less, or about 100 mg or less, may be of interest for drug delivery systems delivered onto or into the eye.

[0070] Typical examples of non-biodegradable or non-bioerodible materials for implants include silicone or PVA (Psivida, etc.) as a semi-permeable membrane.

[0071] Other possible sustained delivery components may be based on cell-based approaches such as encapsulated cell technology; and reservoir-based approaches (foresight4; Replenish).

[0072] The neurotrophic agent, FAS / FASL inhibitor, TNF-α / TNFR inhibitor, and / or mitochondrial peptide may or may not be covalently attached to a sustained delivery component.

[0073] In some embodiments, the neurotrophic agent is covalently attached to the sustained delivery component. In some embodiments, the neurotrophic agent is not covalently attached to the sustained delivery component.

[0074] In some embodiments, the FAS / FASL inhibitor is covalently attached to the sustained delivery component. In some embodiments, the FAS / FASL inhibitor is not covalently attached to the sustained delivery component.

[0075] In some embodiments, the TNF-α / TNFR inhibitor is covalently attached to the sustained delivery component. In some embodiments, the TNF-α / TNFR inhibitor is not covalently attached to the sustained delivery component.

[0076] In some embodiments, the mitochondrial peptide is covalently attached to the sustained delivery component. In some embodiments, the mitochondrial peptide is not covalently attached to the sustained delivery component.

[0077] In some embodiments, the oligonucleotide is covalently linked to a sustained delivery component. In some embodiments, the oligonucleotide is not covalently linked to a sustained delivery component.

[0078] For example, neurotrophic agents may be [ka] wherein Neu-H is a neurotrophic agent such as those described above.

[0079] The oligonucleotide has the formula [ka] wherein Nuc-H is an oligonucleotide such as those described above.

[0080] FAS / FASL inhibitors have the formula [ka] wherein FAS-H is a FAS / FASL inhibitor such as those described above.

[0081] TNF-α / TNFR inhibitors are [ka] and TNF-H is a TNF-α / TNFR inhibitor such as those described above.

[0082] Mitochondrial peptides have the formula [ka] wherein Mit-H is a mitochondrial peptide such as those described above.

[0083] The chemokine inhibitor has the formula [ka] wherein CK-H is a chemokine inhibitor such as those described above.

[0084] Cysteine-aspartic proteases have the formula [ka] wherein CAS-H is a cysteine-aspartic acid protease such as the cysteine-aspartic acid proteases described above.

[0085] For any related structural representation of formula C, 3, 4, II, 5, 6, or 7, R 1 are independently H or C, such as CH3, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, or C6 alkyl. 1ー6 It is alkyl.

[0086] For any related structural representation of formula C, 3, 4, II, 5, 6, or 7, R 2 are independently H or C, such as CH3, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, or C6 alkyl. 1ー6 It is alkyl.

[0087] With respect to the representation of formula C, 3, 4, II, 5, 6, or 7, or any related structure, such as the compounds below, R 3 are independently H or C, such as CH3, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, or C6 alkyl. 1ー6 It is alkyl.

[0088] Examples of compounds of Formula 3 are VGDGGLFEKKL-PEG-Si(OH)3 ("VGDGGLFEKKL" is disclosed as SEQ ID NO: 1) or VGDGGLFEKKL-PEG-SiOR 1 OR 2 OR 3 ("VGDGGLFEKKL" is disclosed as SEQ ID NO: 1), and PEG is a polyethylene glycol chain (e.g., -(OCH2CH2) n - and n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc. In the body, the ester bond can be hydrolyzed to release VGDGGLFEKKL (SEQ ID NO: 1).

[0089] Formula C, or SiO2R of 3-5 1 OR 2 OR 3 The group can be covalently bonded to the silica of a silica-based drug delivery system to form, for example, a compound represented by formula C1, 3D, 4D, or 5D, where D is SiOR of formula C, 3, 4, 5, 6, or 7. 1 OR 2 OR 3 It is a sustained delivery component containing Si.

[0090] [ka]

[0091] The drug delivery system may optionally further comprise an antioxidant such as ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, potassium metabisulfite, propyl gallate, sodium metabisulfite, sodium thiosulfate, vitamin E, 3,4-dihydroxybenzoic acid, or cysteine.

[0092] For some treatments, the drug delivery system may be injected at reduced temperatures to improve performance of the drug delivery system, such as from about −7° C. to about 17° C., from about −7° C. to 0° C., from about 0° C. to about 5° C., from about 5° C. to about 10° C., from about 10° C. to about 17° C., etc. For example, this may provide more sustained delivery of the drug, more consistent drug levels (concentrations), improved efficacy, etc.

[0093] Drug delivery systems (herein referred to as "subject drug delivery systems") comprising a neurotrophic agent, a FAS / FASL inhibitor, a TNF-α / TNFR inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic acid protease, and an optional sustained-delivery component, can be administered to a mammal, such as a human, by any suitable method, such as injection or surgery into a body part, oral administration, or topical application to the eye or skin. In some embodiments, the subject drug delivery systems are injected or otherwise implanted into the eye, including the anterior chamber, posterior chamber, subconjunctival space, or sub-Tenon's space. In some embodiments, the subject drug delivery systems may be injected subcutaneously, or into tissues in or surrounding the heart, brain, or cochlea, into vascular structures such as coronary or cerebral arteries, or directly into cerebrospinal fluid (CSF), or into a reservoir in communication with the CSF or vitreous.

[0094] In some embodiments, the subject drug delivery systems may be injected directly into the heart, injected or implanted intra-arterially (coronary artery), or delivered to the site of myocardial infarction through a catheter.

[0095] In some embodiments, the subject drug delivery systems may be injected directly into the brain, injected or implanted into an artery (typically the carotid, cerebral, or spinal artery), or delivered to the site of infarction (stroke) through a catheter.

[0096] Catheters used to deliver the subject drug delivery systems may be combined with devices used to perform mechanical embolectomy / thrombectomy or stent placement.

[0097] A subject drug delivery system may be administered as a bolus, for example, following embolectomy / thrombectomy or stent placement, or may be continuously injected into the area of ​​interest over a period of 0.1 minutes to 30 days, 0.1-10 minutes, 10-20 minutes, 20-40 minutes, 40-60 minutes, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, 6-8 hours, 8-10 hours, 10-12 hours, 12-18 hours, 18-24 hours, 1-2 days, 2-3 days, 3-4 days, 4-5 days, 5-6 days, 6-7 days, 1-2 weeks, 2-3 weeks, or about 3-4 weeks.

[0098] The subject drug delivery systems can extend the time that a drug remains in the body. For example, the drug delivery systems can provide therapeutic concentrations of a drug for at least about 2 weeks, at least about 4 weeks, at least about 6 weeks, at least about 8 weeks, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 1 year, at least about 1.5 years, at least about 2 years, at least about 3 years, at least about 4 years, about 1-6 months, about 6-12 months, about 12-18 months, about 18-24 months, about 24-36 months, up to about 2 years, up to about 3 years, up to about 4 years, up to about 5 years, or up to about 10 years. The drug delivery systems may be injected, implanted, or modified for a period within any of the above ranges.

[0099] In some embodiments, the subject drug delivery systems are used to treat age-related macular degeneration, retinal artery occlusion, retinal vein occlusion, retinal detachment, central retinopathy, chorioretinopathy, diabetic retinopathy, macular telangiectasia, familial exudative vitreoretinopathy, retinopathy of prematurity, vitreomacular traction, macular hole / pucker, ocular injury, pathologic myopia, uveitis (creeping choroidopathy, sympathetic ophthalmia, birdshot retinochoroidopathy, acute multifocal macular pigment epitheliopathy (AMPPE), Behcet's disease, sarcoidosis, Vogt's disease, and the like. The compound may be administered to a mammal, such as a human, to treat a condition or disease affecting the choroid or retina, such as Koyanagi-Harada syndrome (VKH), oculocutaneous albinism, retinitis pigmentosa (RP), total choroidal atrophy, Leber congenital amaurosis (LCA), Usher syndrome, Stargardt disease, juvenile X-linked retinoschisis, Leber hereditary optic atrophy, Best disease, color vision deficiency, cone-rod dystrophy, gyrate atrophy, juvenile macular degeneration, Kearns-Sayre syndrome, or the like, or a combination thereof.

[0100] In some embodiments, the subject compositions may be administered to a mammal, such as a human, to treat a condition or disease affecting the optic nerve, such as glaucoma (primary open-angle glaucoma (POAG), acute primary angle-closure glaucoma (APACG), chronic angle-closure glaucoma, pigmentary glaucoma, pseudoexfoliation glaucoma, normal-tension glaucoma, childhood glaucoma, and secondary glaucoma), ischemic optic neuropathy, optic neuritis / neuromyelitis optica, Leber's hereditary optic neuropathy, optic atrophy, optic nerve edema, increased intracranial pressure (pseudotumor cerebri), and the like, or a combination thereof.

[0101] In some embodiments, the subject drug delivery systems may be administered or implanted in mammals, such as humans, to treat disorders of the ear, such as Meniere's disease, sensorineural hearing loss, including hearing loss related to, associated with, or caused by ototoxicity, immune-mediated hearing loss, genetic / congenital (including Usher, Alport, Waardenburg) hearing loss, noise-related, noise-related, or noise-induced hearing loss, presbycusis, traumatic hearing loss, vascular collapse-related, vascular collapse-related, or vascular collapse-induced hearing loss, infection-related, infection-related, or infection-induced hearing loss, and the like, or combinations thereof.

[0102] In some embodiments, the subject drug delivery systems are used to treat Alzheimer's disease / dementia, anoxia, stroke, Friedreich's ataxia, ataxia-telangiectasia, Asperger's syndrome (autism), intracranial hypertension (pseudotumor cerebri), traumatic brain injury, concussion, diabetic nephropathy, dystonia, essential tremor, epilepsy, Riley-Day syndrome, gangliosidosis, giant cell arteritis, Guillain-Barré syndrome, Huntington's disease, Refsum's disease, Kearns-Sayre syndrome, and The therapeutic agent may be administered or implanted into a mammal, such as a human, to treat disorders of the central nervous system (CNS), such as other mitochondrial myopathies including Leber's optic neuropathy, amyotrophic lateral sclerosis, multiple system atrophy, myasthenia gravis, neurological complications of AIDS, neuromyelitis optica (Devic's disease), autoimmune encephalitis / myelitis, olivopontocerebellar atrophy, Parkinson's disease, peripheral neuropathy, Pompe disease, shaken baby syndrome, Tay-Sachs disease, Wallenberg syndrome, vasculitis, etc., or combinations thereof.

[0103] Example 1: Solid-phase synthesis of peptide 6-L-MET12 featuring an amide bond Using methods known in the art, peptide 6 was coupled to a resin at the NH2 terminus, protected with a BOC group and a t-Bu ester group, and coupled to NH2-PEG at the carboxylic acid terminus, forming resin-LK(Boc)-K(Boc)-E(tBu)-FLGGD(tBu)-GV-CO2(CH2-CH2-O). nTo provide -CH2-CH2-NH2, the nature of the starting materials and the order of the reactions may be varied to improve efficiency and selectivity; all reactions are carried out using methods known in the art. MET12 is similarly protected. The free amine of the protected peptide 6 compound and the free acid of the protected MET12 can be coupled using any suitable peptide coupling method known in the art. After the coupling reaction, the protected amide can be fully deprotected using TFA or other acid-catalyzed methods known in the art to release the peptide 6-L-MET12 amide derivative. Different orthogonal protecting group strategies may be employed, as needed, to optimize the efficiency of the overall procedure, as is known in the art.

[0104] Example 2: Solid-phase synthesis of peptide 6-L-MET12 featuring an ester bond Using methods known in the art, peptide 6 was linked to a resin at the NH2 terminus, protected on the free amine groups with CBz groups and on the free acid groups with benzyl groups, and coupled to polyethylene glycol at the carboxylic acid terminus, yielding resin-LK(Cbz)-K(Cbz)-E(Bn)-FLGGD(Bn)-GV-CO2(CH2-CH2-O). n To provide -CH2-CH2-OH, the nature of the starting materials and the order of the reactions may be varied to improve selectivity, and all reactions are carried out using methods known in the art. MET12 is similarly protected. The free alcohol terminus of the protected peptide 6 compound and the free acid of the protected MET12 can be coupled using any suitable ester coupling method known in the art. After the coupling reaction, the protected ester can be fully deprotected using hydrogenation or other debenzylation methods known in the art to release the peptide 6-L-MET12 ester derivative. As known in the art, different orthogonal protecting group strategies may be employed as needed to optimize the efficiency of the overall procedure.

[0105] The following embodiments are particularly contemplated by the inventors.

[0106] Embodiment 1. A drug delivery system comprising a neurotrophic agent, a FAS / FASL inhibitor, a TNF-α / TNFR inhibitor, a mitochondrial peptide, a chemokine inhibitor, or a cysteine-aspartic acid protease, and an optional sustained delivery component.

[0107] Embodiment 2. 2. The drug delivery system of embodiment 1, comprising a neurotrophic agent.

[0108] Embodiment 3. 2. The drug delivery system of embodiment 1, comprising a FAS / FASL inhibitor.

[0109] Embodiment 4. 2. The drug delivery system of embodiment 1, comprising a TNF-α / TNFR inhibitor.

[0110] Embodiment 5. 2. The drug delivery system of embodiment 1, comprising a mitochondrial peptide.

[0111] Embodiment 6. 2. The drug delivery system of embodiment 1, comprising both a neurotrophic agent and a FAS / FASL inhibitor.

[0112] Embodiment 7. The drug delivery system of embodiment 6, wherein the neurotrophic agent and the FAS / FASL inhibitor are covalently bonded to each other.

[0113] Embodiment 8. 8. The drug delivery system of embodiment 7, wherein the neurotrophic agent and the FAS / FASL inhibitor are covalently attached to each other via a linking group.

[0114] Embodiment 9. 2. The drug delivery system of embodiment 1, comprising both a neurotrophic agent and a TNF-α / TNFR inhibitor.

[0115] Embodiment 10. 10. The drug delivery system of embodiment 9, wherein the neurotrophic agent and the TNF-α / TNFR inhibitor are covalently bonded to each other.

[0116] Embodiment 11. 11. The drug delivery system of embodiment 10, wherein the neurotrophic agent and the TNF-α / TNFR inhibitor are covalently attached to each other via a linking group.

[0117] Embodiment 12. 2. The drug delivery system of embodiment 1, comprising both a neurotrophic agent and a mitochondrial peptide.

[0118] Embodiment 13. 13. The drug delivery system of embodiment 12, wherein the neurotrophic agent and the mitochondrial peptide are covalently bonded to each other.

[0119] Embodiment 14. 14. The drug delivery system of embodiment 13, wherein the neurotrophic agent and the mitochondrial peptide are covalently attached to each other via a linking group.

[0120] Embodiment 15. 15. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14, wherein the neurotrophic agent comprises a CNTF peptide.

[0121] Embodiment 16. 16. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, wherein the neurotrophic agent comprises peptide 6.

[0122] Embodiment 17. 17. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, wherein the neurotrophic agent comprises peptide 21.

[0123] Embodiment 18. 18. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17, wherein the neurotrophic agent comprises recombinant CNTF.

[0124] Embodiment 19. 19. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18, wherein the neurotrophic agent comprises BDNF.

[0125] Embodiment 20. 20. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19, wherein the neurotrophic agent comprises GDNF.

[0126] Embodiment 21. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, wherein the FAS / FASL inhibitor comprises FLIP.

[0127] Embodiment 22. 22. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21, wherein the FAS / FASL inhibitor comprises MET12.

[0128] Embodiment 23. 23. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22, wherein the FAS / FASL inhibitor comprises ONL1204.

[0129] Embodiment 24. 24. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23, wherein the FAS / FASL inhibitor comprises a FAS apoptosis inhibitor molecule.

[0130] Embodiment 25. 25. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24, wherein the FAS / FASL inhibitor comprises nucleolar protein 3.

[0131] Embodiment 26. 26. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25, wherein the FAS / FASL inhibitor comprises DcR1.

[0132] Embodiment 27. 27. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26, wherein the FAS / FASL inhibitor comprises DcR2.

[0133] Embodiment 28. 28. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27, wherein the FAS / FASL inhibitor comprises DcR3.

[0134] Embodiment 29. 29. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28, wherein the TNF-α / TNFR inhibitor comprises etanercept.

[0135] Embodiment 30. 30. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29, wherein the TNF-α / TNFR inhibitor comprises infliximab.

[0136] Embodiment 31. 31. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, wherein the TNF-α / TNFR inhibitor comprises golimumab.

[0137] Embodiment 32. 32. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31, wherein the TNF-α / TNFR inhibitor comprises certolizumab.

[0138] Embodiment 33. 33. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, or 32, wherein the TNF-α / TNFR inhibitor comprises adalimumab.

[0139] Embodiment 34. 34. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, or 33, wherein the TNF-α / TNFR inhibitor comprises R1antTNF.

[0140] Embodiment 35. 35. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34, wherein the TNF-α / TNFR inhibitor comprises DMS5540.

[0141] Embodiment 36. 36. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35, wherein the TNF-α / TNFR inhibitor comprises TROS.

[0142] Embodiment 37. 37. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36, wherein the TNF-α / TNFR inhibitor comprises ATROSAB.

[0143] Embodiment 38. 38. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, or 37, wherein the mitochondrial peptide comprises humanin.

[0144] Embodiment 39. 39. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or 38, wherein the mitochondrial peptide comprises a humanin analog.

[0145] Embodiment 40. 40. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39, wherein the mitochondrial peptide comprises s14G-humanin.

[0146] Embodiment 41. 41. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, wherein the mitochondrial peptide comprises MTP101.

[0147] Embodiment 42. 42. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41, wherein the sustained delivery component is silica-based.

[0148] Embodiment 43. 43. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, or 42, wherein the sustained delivery component is porous.

[0149] Embodiment 44. 43. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, or 42, wherein the sustained delivery component is non-porous.

[0150] Embodiment 45. 45. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44, wherein the neurotrophic agent is covalently attached to the sustained delivery component.

[0151] Embodiment 46. 46. ​​The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45, wherein the FAS / FASL inhibitor is covalently attached to the sustained delivery component.

[0152] Embodiment 47. 47. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, or 46, wherein the TNF-α / TNFR inhibitor is covalently attached to the sustained delivery component.

[0153] Embodiment 48. 48. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, or 47, wherein the mitochondrial peptide is covalently attached to the sustained delivery component.

[0154] Embodiment 49. 49. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 47, or 48, wherein the neurotrophic agent is not covalently bound to the sustained delivery component.

[0155] Embodiment 50. 50. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 47, 48, or 49, wherein the FAS / FASL inhibitor is not covalently bound to the sustained delivery component.

[0156] Embodiment 51. 51. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 48, 49, or 50, wherein the TNF-α / TNFR inhibitor is not covalently attached to the sustained delivery component.

[0157] Embodiment 52. 53. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51, or 52, wherein the mitochondrial peptide is not covalently bound to the sustained delivery component.

[0158] Embodiment 53. 53. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, wherein the sustained delivery component is of the type described in U.S. Patent No. 9,949,922 to Jokinen et al., issued April 24, 2018.

[0159] Embodiment 54. 53. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, wherein the sustained delivery component is of the type described in U.S. Patent Application Publication No. 20140057996 to Jokinen et al., published February 27, 2014.

[0160] Embodiment 55. 53. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, wherein the sustained delivery component is of the type described in U.S. Patent No. 9,603,801 to Barnett et al., issued March 28, 2017.

[0161] Embodiment 56. 53. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, wherein the sustained delivery component is of the type described in U.S. Patent No. 9,808,421 to Ashton et al., issued November 7, 2017.

[0162] Embodiment 57. 53. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, wherein the sustained delivery component is of the type described in U.S. Patent No. 9,333,173 to Ashton et al., issued May 10, 2016.

[0163] Embodiment 58. 53. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, wherein the sustained delivery component is of the type described in U.S. Patent Publication No. 20140271764 to Ashton et al., published September 28, 2014.

[0164] Embodiment 59. 59. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, or 58, further comprising an oligonucleotide.

[0165] Embodiment 60. A drug delivery system comprising an oligonucleotide and a sustained delivery component.

[0166] Embodiment 61. The drug delivery system of embodiment 59 or 60, wherein the oligonucleotide comprises a small interfering RNA (siRNA).

[0167] Embodiment 62. 60. The drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, or 59, wherein the neurotrophic agent comprises nerve growth factor (NGF).

[0168] Embodiment 63. 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, or 62. A method of treating a condition comprising 1) a genetic or age-related choroidal, retinal, or optic nerve disorder or degeneration, 2) an otic disorder, or 3) a neurological or CNS disorder, comprising administering the drug delivery system of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, or 62 to a mammal in need of such treatment.

[0169] Embodiment 64. 64. The drug delivery system or method of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, or 63, wherein the FAS inhibitor comprises bicyclol.

[0170] Embodiment 65. 64. The drug delivery system or method of embodiment 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, or 63, wherein the chemokine inhibitor comprises NR58.3-14-3.

[0171] (Addendum) (Appendix 1) 1. A drug delivery system comprising a first active pharmaceutical ingredient (API) and a sustained delivery component, wherein the first API is a neurotrophic agent, a FAS / FASL inhibitor, a TNF-α / TNFR inhibitor, a mitochondrial peptide, a chemokine inhibitor, a cysteine-aspartic acid protease, or a combination thereof.

[0172] (Appendix 2) 2. The drug delivery system of claim 1, further comprising a second API, wherein the first API is a neurotrophic agent and the second API is a FAS / FASL inhibitor, a TNF-α / TNFR inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or CASPASE.

[0173] (Appendix 3) 2. The drug delivery system of claim 1, further comprising a second API, wherein the first API is a FAS / FASL inhibitor and the second API is a TNF-α / TNFR inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or CASPASE.

[0174] (Appendix 4) 2. The drug delivery system of claim 1, further comprising a second API, wherein the first API is a TNF-α / TNFR inhibitor and the second API is a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or CASPASE.

[0175] (Appendix 5) 2. The drug delivery system of claim 1, further comprising a second API, wherein the first API is an oligonucleotide and the second API is a chemokine inhibitor or CASPASE.

[0176] (Appendix 6) 10. The drug delivery system of claim 1, further comprising a second API, wherein the first API is a chemokine inhibitor and the second API is CASPASE.

[0177] (Appendix 7) 7. The drug delivery system of claim 1, 2, 3, 4, 5, or 6, wherein the first API and the second API are not covalently bonded to each other.

[0178] (Appendix 8) 7. The drug delivery system of claim 1, 2, 3, 4, 5, or 6, wherein the first API is covalently bonded to the second API.

[0179] (Appendix 9) 9. The drug delivery system of claim 1, wherein the first API is covalently bonded to the sustained delivery component.

[0180] (Appendix 10) 10. The drug delivery system of claim 1, wherein the second API is covalently bonded to the sustained delivery component.

[0181] (Appendix 11) 11. The drug delivery system of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, having about 100 μg to about 1 mg of the first API.

[0182] (Appendix 12) 12. The drug delivery system of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, having about 100 μg to about 1 mg of the second API.

[0183] (Appendix 13) 13. The drug delivery system of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, wherein the implant weighs from about 300 μg to about 10 mg.

[0184] (Appendix 14) 16. A method of treating a condition comprising 1) a genetic or age-related disorder or degeneration of the choroid, retina, or optic nerve, 2) an ear disorder, or 3) a neurological or CNS disorder, comprising administering to a mammal in need of treatment a drug delivery system of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13.

[0185] (Appendix 15) 15. The method of claim 14, wherein the drug delivery system is injected intraocularly into the mammal.

[0186] (Appendix 16) 16. The method of claim 14 or 15, wherein the mammal is a human.

[0187] (Appendix 17) Use of a FAS / FASL inhibitor, a TNF-α / TNFR inhibitor, a mitochondrial peptide, a chemokine inhibitor, a cysteine-aspartic acid protease, or a combination thereof, in the manufacture of a drug delivery system for the treatment of 1) a genetic or age-related choroidal, retinal, or optic nerve disorder or degeneration, 2) an ear disorder, or 3) a neurological or CNS disorder, wherein the drug delivery system further comprises a sustained delivery component.

[0188] (Appendix 18) 18. The use of claim 17, wherein the drug delivery system is injected into the eye of the mammal.

[0189] (Appendix 19) 19. The use of claim 17 or 18, wherein the mammal is a human.

[0190] (Appendix 20) 14. A kit comprising a drug delivery system according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 for the treatment of 1) a genetic or age-related disorder or degeneration of the choroid, retina, or optic nerve, 2) an ear disorder, or 3) a neurological or CNS disorder, and a label with instructions for use of the drug delivery system.

[0191] (Appendix 21) 21. The kit of claim 20, wherein the drug delivery system is injected into the eye of a mammal.

[0192] (Appendix 22) 22. The kit of claim 20 or 21, wherein the mammal is a human.

Claims

[Request 1] A drug delivery system comprising a first active pharmaceutical ingredient (API) and a sustained delivery component, wherein the first API is a peptide derivative of ciliary neurotrophic factor (CNTF) comprising the peptide sequence DGGL, and the first API is a peptide represented by SEQ ID NO: 2 (Peptide 21: Ac-DGGL). Ａ G-NH ２ ) wherein the drug delivery system is injected into the eye of a mammal.

Images